WO2021228141A1 - 抗体药物缀合物及其制备方法和用途 - Google Patents

抗体药物缀合物及其制备方法和用途 Download PDF

Info

Publication number
WO2021228141A1
WO2021228141A1 PCT/CN2021/093348 CN2021093348W WO2021228141A1 WO 2021228141 A1 WO2021228141 A1 WO 2021228141A1 CN 2021093348 W CN2021093348 W CN 2021093348W WO 2021228141 A1 WO2021228141 A1 WO 2021228141A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cancer
seq
sequence
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/093348
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
肖亮
薛彤彤
王晶翼
王成
刘登念
田强
宋帅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/998,772 priority Critical patent/US20230338565A1/en
Priority to CA3178406A priority patent/CA3178406A1/en
Priority to JP2022568760A priority patent/JP7407973B2/ja
Priority to CR20220580A priority patent/CR20220580A/es
Priority to KR1020227043736A priority patent/KR20230012000A/ko
Priority to IL298184A priority patent/IL298184A/en
Priority to MX2022014332A priority patent/MX2022014332A/es
Priority to AU2021270940A priority patent/AU2021270940A1/en
Priority to PE2022002658A priority patent/PE20230373A1/es
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority to EP21804105.1A priority patent/EP4151235A4/en
Priority to CN202180032620.1A priority patent/CN115715202B/zh
Publication of WO2021228141A1 publication Critical patent/WO2021228141A1/zh
Priority to JOJO/P/2022/0306A priority patent/JOP20220306A1/ar
Priority to CONC2022/0016208A priority patent/CO2022016208A2/es
Priority to DO2022000251A priority patent/DOP2022000251A/es
Anticipated expiration legal-status Critical
Priority to JP2023213677A priority patent/JP7734178B2/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the invention belongs to the technical field of biomedicine. Specifically, the present invention relates to an anti-Claudin 18.2 antibody-drug conjugate (ADC) and a composition containing the ADC, and their uses.
  • ADC anti-Claudin 18.2 antibody-drug conjugate
  • the treatment of gastric cancer is mainly based on surgical resection.
  • chemotherapy is the main treatment method, but under existing conditions, chemotherapy can only improve symptoms and prolong survival.
  • biomacromolecule drugs except for Trastuzumab, Ramucirumab, Pembrolizumab, etc., which have been approved, most of the other targeted therapy drugs for gastric cancer have unsatisfactory results or It is still in the early stages of clinical research.
  • the core defect of existing drugs is the unmet clinical needs of non-surgical treatment.
  • the treatment options for advanced or recurrent gastric cancer are very limited, the prognosis is extremely poor, and the mortality rate is high.
  • gastric cancer drugs are currently in great demand.
  • Claudin 18.2 (CLDN 18.2) is a member of the Claudin protein family.
  • Claudin family proteins are a class of proteins that mediate tight junctions between cells.
  • Claudin proteins of different subtypes are expressed in different tissues and are related to different types of cancer.
  • Claudin 18.2 is only expressed in gastric mucosal cells in normal tissues and not expressed in other normal tissues.
  • Claudin 18.2 is highly expressed in 70% of primary gastric adenocarcinoma and its metastases. It is also expressed in other cancers such as pancreatic cancer, esophageal cancer and non-small cell lung cancer. The highly specific expression of Claudin 18.2 in tumor tissues makes Claudin 18.2 a very good target for tumor immunotherapy.
  • ADC Claudin 18.2 antibody-drug conjugate
  • the inventors connected an antibody with high affinity and specific binding to Claudin 18.2 to a biologically active molecule through a linker to obtain a class of antibody-drug conjugates targeting Claudin 18.2 and a composition containing the conjugate.
  • the conjugate or composition has high killing activity against some tumor cells expressed by Claudin 18.2.
  • the conjugate can effectively inhibit the growth of Claudin 18.2 positive tumors, especially gastric cancer or gastric adenocarcinoma, and has high safety.
  • the present invention provides an antibody-drug conjugate that specifically binds to human CLDN 18.2, the structure of which is shown in formula (I),
  • D is a biologically active molecule fragment
  • L is a linker
  • ⁇ is selected from an integer between 1-10 (such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10); preferably, ⁇ is selected from an integer between 1-8 (such as 1, 2, 3, 4, 5, 6, 7 or 8);
  • A is an antibody or an antigen-binding fragment thereof that specifically binds to human CLDN 18.2.
  • the antibody or antigen-binding fragment thereof that specifically binds to human CLDN18.2 comprises:
  • CDR-L1, CDR-L2 and CDR-L3 contained in the VL (light chain variable region) shown in SEQ ID NO: 15 or 24;
  • the following three light chain CDRs (1) the CDR-L1 or its variants containing amino acid mutations, (1) the CDR-L2 or its variants containing amino acid mutations, CDR-L3 described in (1) or a variant containing amino acid mutations compared with it;
  • At least one of the three heavy chain CDRs and/or three light chain CDRs described in (2) contains amino acid mutations compared with the corresponding CDRs in (1), and the amino acid mutations are one or several amino acids
  • the substitution, deletion or addition for example, substitution, deletion or addition of 1, 2, or 3 amino acids
  • the antibody or antigen-binding fragment containing the mutation can still specifically bind to CLDN 18.2; preferably, specifically Combines human CLDN 18.2; preferably, the substitution is a conservative substitution.
  • the CDRs are defined according to the IMGT or AbM numbering system.
  • the antibody or antigen-binding fragment thereof further includes framework regions (FRs) from human immunoglobulins.
  • FRs framework regions
  • the antibody or antigen-binding fragment thereof comprises:
  • the three light chain CDRs defined by the IMGT numbering system are as follows: CDR-L1 with the sequence of SEQ ID No: 4, CDR-L2 with the sequence of SEQ ID No: 5, and CDR-L3 with the sequence of SEQ ID No: 6;
  • CDR-L1 described in (1-1) or its variants containing amino acid mutations
  • CDR-L2 described in (1-1) or its variants containing amino acid mutations
  • At least one of the three heavy chain CDRs and/or three light chain CDRs contains an amino acid mutation compared with the corresponding CDR in (1-1), and the amino acid mutation is a substitution of one or several amino acids , Deletion or addition (for example, substitution, deletion or addition of 1, 2, or 3 amino acids); the antibody or antigen-binding fragment containing the mutation can still specifically bind to human CLDN 18.2; preferably, the The substitution is a conservative substitution;
  • the three light chain CDRs defined by the AbM numbering system are as follows: CDR-L1 with the sequence of SEQ ID No: 10, CDR-L2 with the sequence of SEQ ID No: 11, and CDR-L3 with the sequence of SEQ ID No: 12;
  • CDR-L1 described in (2-1) or its variants containing amino acid mutations and CDR-L2 described in (2-1) or its variants containing amino acid mutations
  • CDR-L3 described in (2-1) or a variant containing amino acid mutations compared with it A variant of CDR-L3 described in (2-1) or a variant containing amino acid mutations compared with it;
  • At least one of the three heavy chain CDRs and/or three light chain CDRs contains an amino acid mutation compared with the corresponding CDR in (2-1), and the amino acid mutation is a substitution of one or several amino acids , Deletion or addition (for example, substitution, deletion or addition of 1, 2 or 3 amino acids); the antibody or antigen-binding fragment containing the mutation can still specifically bind to human CLDN 18.2; preferably, the Substitutions are conservative substitutions.
  • the antibody or antigen-binding fragment thereof further includes framework regions (FRs) from human immunoglobulins.
  • FRs framework regions
  • the antibody or antigen-binding fragment thereof comprises:
  • VH and/or VL where CDRs are defined according to the IMGT numbering system:
  • (1-1) VH containing the following 3 CDRs: CDR-H1 with the sequence of SEQ ID No: 1, CDR-H2 with the sequence of SEQ ID Nos: 2 or 21, and CDR of the sequence SEQ ID No: 3 -H3; and/or,
  • VL containing the following 3 CDRs: CDR-L1 with the sequence of SEQ ID No: 4, CDR-L2 with the sequence of SEQ ID No: 5, and CDR-L3 with the sequence of SEQ ID No: 6;
  • At least one CDR contains a mutation, which is a substitution, deletion or addition of one or several amino acids or any combination thereof (for example, 1 One, two or three amino acid substitutions, deletions or additions or any combination thereof); preferably, the substitution is a conservative substitution; the antibody or antigen-binding fragment containing the mutation can still specifically bind to CLDN 18.2 ; Preferably, it specifically binds to human CLDN 18.2;
  • VH and/or VL where CDRs are defined according to the AbM numbering system:
  • VL containing the following 3 CDRs: CDR-L1 with the sequence of SEQ ID No: 10, CDR-L2 with the sequence of SEQ ID No: 11, and CDR-L3 with the sequence of SEQ ID No: 12;
  • At least one CDR contains a mutation, which is a substitution, deletion or addition of one or several amino acids or any combination thereof (for example, 1 One, two or three amino acid substitutions, deletions or additions or any combination thereof); preferably, the substitution is a conservative substitution; the antibody or antigen-binding fragment containing the mutation can still specifically bind to CLDN 18.2 ; Preferably, it specifically binds to human CLDN 18.2.
  • a mutation which is a substitution, deletion or addition of one or several amino acids or any combination thereof (for example, 1 One, two or three amino acid substitutions, deletions or additions or any combination thereof); preferably, the substitution is a conservative substitution; the antibody or antigen-binding fragment containing the mutation can still specifically bind to CLDN 18.2 ; Preferably, it specifically binds to human CLDN 18.2.
  • the VH and/or VL of the antibody or antigen-binding fragment thereof includes framework regions (FRs) from human or murine immunoglobulins.
  • the antibody or antigen-binding fragment thereof comprises:
  • the VH contained in the antibody or antigen-binding fragment thereof has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%. %, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity; and/or, the antibody or antigen-binding fragment thereof Compared with the VL described in (1), the contained VL has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%.
  • the antibody or antigen-binding fragment thereof containing the same sequence can still specifically bind to CLDN 18.2; preferably, Specifically bind to human CLDN 18.2;
  • the VH contained in the antibody or antigen-binding fragment has one or several amino acid substitutions, deletions or additions or any combination thereof (for example, one, two , 3, 4 or 5 amino acid substitutions, deletions or additions or any combination thereof); and/or, the VL contained in the antibody or antigen-binding fragment thereof is compared with the VL described in (1), Have one or several amino acid substitutions, deletions or additions or any combination thereof (for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions or any combination thereof); preferably, the The substitutions are conservative substitutions.
  • the mutation-containing antibody or antigen-binding fragment thereof can still specifically bind to CLDN 18.2; preferably, it specifically binds to human CLDN 18.2.
  • the antibody or antigen-binding fragment thereof may further comprise a constant region derived from a mammalian (e.g., murine or human) immunoglobulin or a variant thereof.
  • the antibody may comprise:
  • the CH (heavy chain constant region) of a human immunoglobulin or a variant thereof which has one or more amino acid substitutions, deletions or additions (for example, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions, or additions; for example, 1, 2, 3, 4, or 5 amino acid substitutions, deletions, or additions); and/or ,
  • CL light chain constant region of human immunoglobulin or a variant thereof, which has one or more amino acid substitutions, deletions or additions (for example, up to 20, up to 15, up to 10, or up to 5 amino acid substitutions, deletions, or additions; for example, 1, 2, 3, 4, or 5 amino acid substitutions, deletions, or additions).
  • the constant region is changed, for example, mutated to modify the properties of the anti-CLDN18.2 antibody molecule (e.g., to change one or more of the following properties: Fc receptor binding, antibody glycosylation, cysteine Number of amino acid residues, effector cell function or complement function).
  • the function can be changed by replacing at least one amino acid residue in the constant region of the antibody with a different residue, for example, changing the affinity of the antibody to the effector ligand (such as FcR or complement C1q), thereby changing the effector function (such as enhancing ).
  • the constant region is altered to alter (eg enhance) antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular phagocytosis (ADCP).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • the CH is an IgG heavy chain constant region, such as an IgG1, IgG2, IgG3, or IgG4 heavy chain constant region.
  • the antibody or antigen-binding fragment thereof comprises the heavy chain constant region of human IgG1.
  • the antibody or antigen-binding fragment thereof comprises CH as shown in SEQ ID NO: 16 or a variant thereof, which has conservative substitutions of up to 20 amino acids compared with SEQ ID NO: 16 (For example, conservative substitutions of up to 15, up to 10, or up to 5 amino acids; for example, conservative substitutions of 1, 2, 3, 4, or 5 amino acids).
  • the CH containing mutations retains substantially the same function as SEQ ID NO: 16.
  • the CL is selected from the light chain constant region of kappa or lambda.
  • the CL is a kappa light chain constant region (e.g., human kappa light chain).
  • the antibody or antigen-binding fragment thereof comprises CL as shown in SEQ ID NO: 17, or a variant thereof, which has conservative substitutions of up to 20 amino acids compared to SEQ ID NO: 17 (For example, conservative substitutions of up to 15, up to 10, or up to 5 amino acids; for example, conservative substitutions of 1, 2, 3, 4, or 5 amino acids).
  • the CL containing the mutation retains substantially the same function as SEQ ID NO: 17.
  • the antibody or antigen-binding fragment thereof comprises CH as shown in SEQ ID NO: 16 and/or CL as shown in SEQ ID NO: 17.
  • the antibody includes a heavy chain composed of the VH of the sequence shown in SEQ ID NO: 13 and the CH of SEQ ID NO: 16, and,
  • the antibody includes a heavy chain consisting of the VH of the sequence shown in SEQ ID NO: 14 and the CH of SEQ ID NO: 16, and,
  • the antibody or antigen-binding fragment thereof comprises:
  • the heavy chain which comprises an amino acid sequence selected from the following:
  • sequence shown in SEQ ID NO: 18 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or 100% sequence identity;
  • sequence shown in SEQ ID NO: 20 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or 100% sequence identity.
  • substitutions described in (1-2) and (2-2) above are conservative substitutions.
  • the CH containing mutations retains substantially the same function as SEQ ID NO: 16.
  • the antibody or antigen-binding fragment thereof comprises:
  • the heavy chain which comprises an amino acid sequence selected from the following:
  • sequence shown in SEQ ID NO: 19 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or 100% sequence identity;
  • sequence shown in SEQ ID NO: 20 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or 100% sequence identity.
  • substitutions described in (1-2) and (2-2) above are conservative substitutions.
  • the aforementioned antibodies or antigen-binding fragments containing mutations or identical sequences can still specifically bind to human CLDN 18.2.
  • the antibody or antigen-binding fragment thereof is selected from ScFv, Fab, Fab', (Fab') 2 , Fv fragments, disulfide-linked Fv (dsFv), diabody, bispecific Sex antibodies and multispecific antibodies.
  • the (DL) ⁇ - A structure is as shown in formula (II):
  • each of R 1 and R 2 is independently hydrogen (such as protium or deuterium), halogen, carboxylic acid, sulfonic acid, cyano, C 1-6 alkyl, halogenated C 1-6 alkyl, cyano substituted C 1-6 alkyl (for example -CH 2 CN), C 1-6 alkoxy, C 2-10 alkenyl or C 2-10 alkynyl;
  • Z 1 is an amino acid or a peptide composed of 2-10 amino acids ;
  • X 1 and x 2 are each independently 0,1,2,3,4,5 or 6; and L 1 is connected at the position D 1, L 1 is at position 2 is connected to L 2;
  • L 2 is Wherein, y 1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and L 2 is connected to L 1 at position 1, and L 2 is connected to L 3 at position 2;
  • L 3 is selected from 5-12 membered heteroaromatic ring
  • L 4 is Wherein Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene and C 3-8 cycloalkylene; R 3 is selected from hydrogen (such as protium or deuterium) and C 1-6 alkyl; Z 3 does not exist or is selected from C 1-6 alkylene; or, R 3 and Z 3 together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; ⁇ is 0, 1 , 5, or 6, and at the second position E and L 4 is connected, is connected at a position L 4 and L 3;
  • each R 4 is independently hydrogen (such as protium or deuterium), ⁇ is 0, 1, 2, 3, 4, 5, or 6, and the 2 position of E is connected to A, and the 1 position of E is connected to L 4 Connected
  • n 1 , m 2 and m 3 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • A, D and ⁇ are as described above.
  • the (DL) ⁇ - A structure is as shown in formula (III):
  • R 5 and R 6 are each independently hydrogen (such as protium or deuterium) or C 1-6 alkyl; x 3 is 1, 2, 3, 4, 5 or 6; and, if L 1 'is present, it Connect with D at position 1 and connect with L 1 at position 2.
  • each of R 1 and R 2 is independently hydrogen (such as protium or deuterium), halogen, carboxylic acid, sulfonic acid, cyano, C 1-6 alkyl, halogenated C 1-6 alkyl, cyano substituted C 1-6 alkyl (for example -CH 2 CN), C 1-6 alkoxy, C 2-10 alkenyl or C 2-10 alkynyl;
  • Z 1 is an amino acid or a peptide composed of 2-10 amino acids ;
  • X 1 and x 2 are each independently 0, 1 , 2, 3, 4, 5 or 6; and, at position 1 of L 1 is connected to L 1 '(when L 1 ' exists), or, L 1 Connected to D at position 1 of L (when L 1 'does not exist); Connected to L 5 at position 2 of L 1;
  • L 5 is Wherein, R 7 is hydrogen or C 1-6 alkyl, or R 7 is connected to the N atom on ⁇ -C to form a 5-6 membered heterocyclic group; x 4 is 1, 2, 3, 4, 5 or 6; y 1 is 0, 1, 2, 3, 4, 5, 6 , 7, 8, 9 or 10; and L 5 is connected to L 1 at position 1, and L 5 is connected to L 3 at position 2;
  • L 3 is selected from 5-12 membered heteroaromatic ring
  • L 4 is Wherein Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene and C 3-8 cycloalkylene; R 3 is selected from hydrogen (such as protium or deuterium) and C 1-6 alkyl; Z 3 does not exist or is selected from C 1-6 alkylene; or, R 3 and Z 3 together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; ⁇ is 0, 1 , 5, or 6, and at the second position E and L 4 is connected, is connected at a position L 4 and L 3;
  • each R 4 is independently hydrogen (such as protium or deuterium), ⁇ is 0, 1, 2, 3, 4, 5, or 6, and the 2 position of E is connected to A, and the 1 position of E is connected to L 4 Connected
  • n 1 , m 2 , m 3 and m 4 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • A, D and ⁇ are as described above.
  • L 1 in the antibody-drug conjugate represented by formula (II) or formula (III) is Wherein, Z 1 is an amino acid or a peptide composed of 2-5 amino acids, wherein the amino acid is selected from Lys, Cit, Val, D-Val, Phe, Leu, Gly, Ala and Asn; preferably, Z 1 is selected from Cit , Lys, Cit-Val and Ala-Val.
  • L 1 is N
  • L 1 is N
  • L 2 in the antibody-drug conjugate represented by formula (II) is And m 1 is 1.
  • L 3 in the antibody-drug conjugate represented by formula (II) or formula (III) is a 5-6 membered heteroaromatic ring, and m 2 is 1.
  • L 3 is triazole, and m 2 is 1.
  • L 4 in the antibody-drug conjugate represented by formula (II) or formula (III) is Wherein Z 2 is a C 1-6 alkylene group, Z 3 is a C 1-6 alkylene group; and m 3 is 1.
  • L 4 is And m 3 is 1.
  • L 1 ′ in the antibody-drug conjugate represented by formula (III) is
  • L 5 in the antibody-drug conjugate represented by formula (III) is Wherein, x 4 is 1, 2, 3 , 4, 5, or 6; y 1 is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • L 5 in the antibody-drug conjugate represented by formula (III) is
  • D in the antibody-drug conjugate represented by formula (III) is
  • D-[L 1 -(L 2 ) m1 -(L 3 ) m2 -(L 4 ) m3 -E]- in the antibody-drug conjugate represented by formula (II) is
  • the structure of the antibody-drug conjugate represented by formula (II) is:
  • ⁇ is selected from an integer between 1-10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is the aforementioned antibody that specifically binds to human CLDN 18.2 or its Antigen-binding fragments.
  • the antibody-drug conjugate represented by formula (II) is represented by the following formula:
  • ⁇ is an integer from 1 to 10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is 2C6.9-hz21.
  • the structure of the antibody-drug conjugate represented by formula (III) is:
  • ⁇ is selected from an integer between 1-10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is the aforementioned antibody that specifically binds to human CLDN 18.2 or its Antigen-binding fragments.
  • the antibody-drug conjugate represented by formula (III) is represented by the following formula:
  • ⁇ is an integer from 1 to 10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is 2C6.9-hz21.
  • the structure of the antibody-drug conjugate represented by formula (III) is:
  • ⁇ is selected from an integer between 1-10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is the aforementioned antibody that specifically binds to human CLDN 18.2 or its Antigen-binding fragments.
  • the antibody-drug conjugate represented by formula (III) is represented by the following formula:
  • ⁇ is an integer from 1 to 10, for example, ⁇ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and A is 2C6.9-hz21.
  • the present invention also provides a composition containing one or more of the above-mentioned antibody-drug conjugates, in which the biologically active molecule fragments (ie D in formula (I)) specifically bind to
  • the molar ratio (DAR value) of the antibody of CLDN18.2 or its antigen-binding fragment (i.e., A in formula (I)) is a decimal or integer between 1-10 (for example, a decimal or integer between 1-8).
  • the composition further contains the aforementioned antibody or antigen-binding fragment thereof.
  • the composition contains 2C6.9-TL001. In some embodiments, the composition is 2C6.9-TL001.
  • the composition contains 2C6.9-TL002. In some embodiments, the composition is 2C6.9-TL002.
  • the composition contains 2C6.9-TL003. In some embodiments, the composition is 2C6.9-TL003.
  • the antibody or antigen-binding fragment thereof of the present invention may be derivatized, for example, linked to another molecule (for example, another polypeptide or protein).
  • another molecule for example, another polypeptide or protein.
  • the derivatization (eg, labeling) of the antibody or antigen-binding fragment thereof will not adversely affect its binding to CLDN 18.2 (especially human CLDN 18.2). Therefore, the antibodies or antigen-binding fragments thereof of the present invention are also intended to include such derivatized forms.
  • bispecific antibody is produced by cross-linking two or more antibodies (of the same type or of different types).
  • Methods for obtaining bispecific antibodies are well known in the art, and examples thereof include, but are not limited to, chemical cross-linking methods, cell engineering methods (hybrid hybridoma methods), or genetic engineering methods.
  • Another type of derivatized antibody is a labeled antibody.
  • the antibody or antigen-binding fragment thereof of the present invention can be linked to a detectable label.
  • the detectable label of the present invention can be any substance that can be detected by fluorescence, spectroscopy, photochemistry, biochemistry, immunology, electrical, optical or chemical means.
  • Such labels are well known in the art, examples of which include, but are not limited to, enzymes (for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radioactive nuclear (E.g., 3H, 125I, 35S, 14C or 32P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin ( PE), Texas red, rhodamine, quantum dots or cyanine dye derivatives (e.g.
  • enzymes for example, horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.
  • radioactive nuclear E.g., 3H, 125I, 35S, 14C or 32P
  • the detectable label as described above can be detected by methods known in the art.
  • a radioactive label can be detected using photographic film or a scintillation calculator, and a fluorescent label can be detected using a light detector to detect the emitted light.
  • Enzyme markers are generally detected by providing a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric markers are detected by simply visualizing colored markers.
  • such labels can be suitable for immunological detection (e.g., enzyme-linked immunoassay, radioimmunoassay, fluorescent immunoassay, chemiluminescence immunoassay, etc.).
  • the detectable label as described above can be connected to the antibody or antigen-binding fragment thereof of the present invention through linkers of different lengths to reduce potential steric hindrance.
  • the antibody or antigen-binding fragment thereof contained in the antibody-drug conjugate of the present invention is one or more of the aforementioned derivatized antibodies or antigen-binding fragments thereof.
  • the present invention also provides a pharmaceutical composition.
  • the pharmaceutical composition contains one or more of the aforementioned antibody-drug conjugates or compositions.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
  • the pharmaceutical composition further contains other ingredients with anti-tumor activity.
  • the antibody-drug conjugate or composition and other ingredients with anti-tumor activity are in the same formulation unit, or in different formulation units. Therefore, the antibody-drug conjugate or composition of the present invention and other ingredients with anti-tumor activity can be administered simultaneously, separately or sequentially.
  • the other ingredients with anti-tumor activity are biologically active polypeptides or active tablets or chemotherapeutic drugs.
  • the biologically active polypeptide is selected from immune checkpoint inhibitors (e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody), or cytokines (e.g., interferon , IL-2, IL-15, GM-CSF, IL-7, IL-12, IL-18, IL-21).
  • immune checkpoint inhibitors e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody
  • cytokines e.g., interferon , IL-2, IL-15, GM-CSF, IL-7, IL-12, IL-18, IL-21.
  • the chemotherapeutic drug is selected from one or more of epirubicin, oxaliplatin, capecitabine, 5-fluorouracil, folinic acid, paclitaxel, and albumin-bound paclitaxel.
  • the other ingredients with anti-tumor activity are a combination of epirubicin, oxaliplatin and 5-fluorouracil, or a combination of oxaliplatin, leucovorin and 5-fluorouracil.
  • the antibody-drug conjugate or composition in the pharmaceutical composition of the invention is sufficient in a subject:
  • tumor cells especially gastric cancer cells, such as gastric adenocarcinoma cells
  • tumor cells especially gastric cancer cells, such as gastric adenocarcinoma cells
  • the present invention provides the use of the antibody-drug conjugate, the composition, and the pharmaceutical composition in the preparation of drugs for the prevention and/or treatment and/or adjuvant treatment of tumors.
  • the tumor is selected from solid tumors, hematological tumors, and metastatic, refractory, or recurrent lesions of cancer.
  • the tumor or cancer is selected from the group consisting of esophageal cancer, gastrointestinal cancer, gastric adenocarcinoma, pancreatic cancer, thyroid cancer, colorectal cancer, kidney cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, gastric cancer, stomach cancer Esophageal junction (GEJ) adenocarcinoma, head and neck cancer, bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, germ cell cancer, bone cancer, skin cancer, thymic cancer, cholangiocarcinoma, gallbladder Cancer, melanoma, mesothelioma, lymphoma, myeloma (e.g. multiple myeloma), sarcoma, glioblastoma, leukemia.
  • lung cancer e.g. non-small cell lung cancer
  • liver cancer gastric cancer
  • the tumor is selected from gastric cancer, gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, esophageal cancer, gastrointestinal cancer, pancreatic cancer, lung cancer (e.g., non-small cell lung cancer).
  • gastric cancer gastric adenocarcinoma
  • GEJ gastroesophageal junction
  • esophageal cancer e.g., esophageal cancer
  • gastrointestinal cancer e.g., pancreatic cancer
  • lung cancer e.g., non-small cell lung cancer
  • the tumor is gastric cancer, gastric adenocarcinoma, or gastroesophageal junction (GEJ) adenocarcinoma, such as locally advanced unresectable or metastatic gastric cancer, gastric adenocarcinoma, or gastroesophageal junction (GEJ) adenocarcinoma.
  • GEJ gastroesophageal junction
  • the tumor is CLDN18.2 positive, and further, the tumor is HER2 negative.
  • the tumor is HER2 negative.
  • the present invention provides a method of preventing and/or treating tumors in a subject. In another aspect, the invention provides a method of delaying tumor progression in a subject. In another aspect, the present invention provides a method of reducing or inhibiting tumor recurrence in a subject. The method described above includes administering an effective amount of the antibody-drug conjugate, composition or pharmaceutical composition of the present invention to a subject in need thereof.
  • the method described above further comprises administering a second therapy to the subject, the second therapy selected from surgery, chemotherapy, radiotherapy, immunotherapy, gene therapy, DNA therapy, RNA therapy, nanotherapy , Viral therapy, adjuvant therapy and any combination thereof.
  • the second therapy can be applied separately or in combination with the methods described above; or, the second therapy can be applied separately or in combination with the methods described above simultaneously or sequentially.
  • the second therapy is chemotherapy.
  • the chemotherapy drug is selected from one or more of epirubicin, oxaliplatin, capecitabine, 5-fluorouracil, folinic acid, paclitaxel, and albumin-bound paclitaxel.
  • the chemotherapy drug is a combination of epirubicin, oxaliplatin and 5-fluorouracil, or a combination of oxaliplatin, leucovorin and 5-fluorouracil.
  • the combined dosing regimen of oxaliplatin, leucovorin, and 5-fluorouracil is selected from FOLFOX4, FOLFOX6, or m FOLFOX6.
  • the second therapy is immunotherapy.
  • the immunotherapy drugs are selected from immune checkpoint inhibitors (e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody), or cytokines (e.g., interference Vegetarian, IL-2, IL-15, GM-CSF, IL-7, IL-12, IL-18, IL-21).
  • immune checkpoint inhibitors e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody
  • cytokines e.g., interference Vegetarian, IL-2, IL-15, GM-CSF, IL-7, IL-12, IL-18, IL-21.
  • the tumor is selected from solid tumors, hematological tumors, and metastatic, refractory, or recurring lesions of cancer.
  • the tumor or cancer is selected from the group consisting of esophageal cancer, gastrointestinal cancer, gastric adenocarcinoma, pancreatic cancer, thyroid cancer, colorectal cancer, kidney cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, gastric cancer, stomach cancer Esophageal junction (GEJ) adenocarcinoma, head and neck cancer, bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, germ cell cancer, bone cancer, skin cancer, thymic cancer, cholangiocarcinoma, gallbladder Cancer, melanoma, mesothelioma, lymphoma, myeloma (e.g. multiple myeloma), sarcoma, glioblastoma, leukemia.
  • lung cancer e.g. non-small cell lung cancer
  • liver cancer gastric cancer
  • the tumor is selected from gastric cancer, gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, esophageal cancer, gastrointestinal cancer, pancreatic cancer, and lung cancer (e.g., non-small cell lung cancer).
  • gastric cancer gastric adenocarcinoma
  • GEJ gastroesophageal junction
  • esophageal cancer e.g., gastrointestinal cancer
  • pancreatic cancer e.g., non-small cell lung cancer
  • the tumor is gastric cancer, gastric adenocarcinoma, or gastroesophageal junction (GEJ) adenocarcinoma, such as locally advanced unresectable or metastatic gastric cancer, gastric adenocarcinoma, or gastroesophageal junction (GEJ) adenocarcinoma.
  • GEJ gastroesophageal junction
  • the tumor is CLDN18.2 positive, and further, the tumor is HER2 negative.
  • the tumor is HER2 negative.
  • the antibody-drug conjugate, composition or pharmaceutical composition of the present invention can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders , Granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injections and concentrated solutions for injections), inhalants, sprays, etc.
  • the preferred dosage form depends on the intended mode of administration and therapeutic use.
  • the pharmaceutical composition of the present invention should be sterile and stable under the conditions of production and storage.
  • a preferred dosage form is injection. Such injection may be a sterile injection solution.
  • a sterile injectable solution can be prepared by the following method: incorporating the necessary dose of the antibody-drug conjugate or composition in a suitable solvent, and optionally, simultaneously incorporating other desired ingredients (including but not Limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filtration and sterilization.
  • the sterile injection solution can be prepared as a sterile lyophilized powder (for example, by vacuum drying or freeze drying) for storage and use.
  • sterile lyophilized powder can be dispersed in a suitable carrier, such as sterile pyrogen-free water, before use.
  • the antibody-drug conjugate of the present invention may be present in a pharmaceutical composition in a unit dosage form for ease of administration.
  • the antibody-drug conjugate, composition or pharmaceutical composition of the present invention can be administered by any suitable method known in the art, including but not limited to oral, oral, sublingual, ocular, topical, parenteral, rectal , Intraleaf sheath, intracytoplasmic reticulum, groin, bladder, topical (eg powder, ointment or drops), or nasal route.
  • the preferred route/mode of administration is parenteral (eg, intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
  • the route and/or manner of administration will vary according to the intended purpose.
  • the antibody-drug conjugate, composition or pharmaceutical composition of the present invention is administered by intravenous infusion or injection.
  • the pharmaceutical composition of the present invention may include a "therapeutically effective amount” or a “prophylactically effective amount” of the antibody-drug conjugate or composition of the present invention.
  • “Prophylactically effective amount” refers to an amount sufficient to prevent, prevent, or delay the occurrence of a disease.
  • “Therapeutically effective amount” refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient who has already suffered from the disease.
  • the therapeutically effective amount of the antibody-drug conjugate or composition of the present invention may vary according to the following factors: the severity of the disease to be treated, the overall state of the patient’s own immune system, and the patient’s general conditions such as age, weight, and gender , The way the drug is administered, and other treatments that are administered at the same time, and so on.
  • the dosage regimen can be adjusted to obtain the best objective response (for example, therapeutic or preventive response).
  • the best objective response for example, therapeutic or preventive response
  • it can be administered in a single dose, it can be administered multiple times over a period of time, or the dose can be reduced or increased proportionally according to the urgency of the treatment situation.
  • the typical non-limiting range of the therapeutically or prophylactically effective amount of the antibody-drug conjugate or composition of the present invention is 0.02-100 mg/kg, for example 0.1-100 mg/kg, 0.1-50 mg/kg, or 1-50 mg/kg. It should be noted that the dosage may vary depending on the type and severity of the symptoms to be treated. In addition, those skilled in the art understand that for any particular patient, the specific dosing regimen should be adjusted over time according to the needs of the patient and the professional evaluation of the doctor; the dosage range given here is for illustrative purposes only, and is not limited The use or scope of the pharmaceutical composition of the present invention.
  • the subject may be a mammal, such as a human.
  • FR Antibody framework region amino acid residues other than CDR residues in the variable region of the antibody
  • Kabat The immunoglobulin comparison and numbering system proposed by Elvin A. Kabat (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991 ).
  • Chothia The immunoglobulin numbering system proposed by Chothia et al. is a classic rule for identifying the boundaries of CDR regions based on the position of structural loop regions (see, for example, Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. People (1989) Nature 342:878-883).
  • IMGT is based on the international immunogenetics information system (The international ImMunoGeneTics information) initiated by Lefranc et al. (IMGT)) for the numbering system, please refer to Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003.
  • conjugate or “conjugate” are interchangeable and refer to a substance obtained by connecting a biologically active molecule to an antibody through a linker, and the English name is ADC (antibody-drug conjugate).
  • the linker can be connected to the antibody through various chemical bonds.
  • the linker is connected by forming a thioether bond with the sulfhydryl group of the antibody.
  • ADC molecules such as 2C6.9-TL001, 2C6.9-TL002, or 2C6.9-TL003 ADC molecules
  • -S- only represents the thioether bond formed by the linker and the sulfhydryl group of the antibody, It does not mean that -S- is part of the linker.
  • ADC of the present application can be represented by (DL) ⁇ - A, where D is a biologically active molecular fragment; L is a linker; A is an antibody or antigen-binding fragment that specifically binds to human CLDN 18.2; ⁇ is selected from 1. An integer between -10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. ⁇ refers to the number of (DL) attached to each antibody molecule, which is an integer. However, in the ADC preparation process, each antibody molecule may be connected to a different number of (DL). Therefore, generally speaking, the product of the ADC is a composition coupled with a different number of (DL) antibodies. In practice, DAR is usually used to represent the average value of the number of antibodies (DL) attached.
  • antibody refers to an immunoglobulin molecule usually composed of two pairs of polypeptide chains (each pair has a light chain (LC) and a heavy chain (HC)).
  • Antibody light chains can be classified into kappa (kappa) and lambda (lambda) light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids.
  • Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the heavy chain constant region is composed of 3 domains (CH1, CH2, and CH3).
  • Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL).
  • the constant region of the light chain consists of a domain CL.
  • the constant domain does not directly participate in the binding of antibodies and antigens, but exhibits a variety of effector functions, such as mediating immunoglobulins and host tissues or factors, including various cells of the immune system (for example, effector cells) and classical complement The combination of the first component (C1q) of the system.
  • VH and VL regions can also be subdivided into regions with hyperdenaturation (called complementarity determining regions (CDR)), interspersed with more conservative regions called framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
  • the variable regions (VH and VL) of each heavy chain/light chain pair respectively form an antigen binding site.
  • the allocation of amino acids in each region or domain can follow Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J.
  • CDR complementarity determining region
  • the precise boundaries of these amino acid residues can be defined according to various numbering systems known in the art, for example, according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia numbering system (Chothia & Lesk (1987) J.Mol. Biol. 196:901-917; Chothia et al.
  • the CDR contained in the antibody or antigen-binding fragment thereof of the present invention can be determined according to various numbering systems known in the art. In certain embodiments, the CDR contained in the antibody or antigen-binding fragment thereof of the present invention is preferably determined by the IMGT or AbM numbering system.
  • framework region or "FR” residues refers to those amino acid residues in the variable region of an antibody other than the CDR residues as defined above.
  • the term "antigen-binding fragment" of an antibody refers to a polypeptide of a fragment of an antibody, such as a polypeptide of a fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/ Or compete with the full-length antibody for specific binding to the antigen, which is also referred to as the "antigen-binding portion".
  • an antibody such as a polypeptide of a fragment of a full-length antibody, which retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/ Or compete with the full-length antibody for specific binding to the antigen, which is also referred to as the "antigen-binding portion”.
  • antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb and complementarity determining regions (CDR) Fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, linear antibodies, nanobodies (technology from Domantis), domain antibodies (technology from Ablynx), and such polypeptides, It contains at least a portion of an antibody sufficient to confer specific antigen binding ability to the polypeptide.
  • Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23:1126-1136.
  • full-length antibody means an antibody composed of two “full-length heavy chains” or “heavy chains” and two “full-length light chains” or “light chains”.
  • full-length heavy chain or “heavy chain” refers to a polypeptide chain that consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, and a hinge region ( HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain; and, when the full-length antibody is of an IgE isotype, it optionally also includes a heavy chain constant region CH4 domain.
  • the "full-length heavy chain” is a polypeptide chain composed of VH, CH1, HR, CH2, and CH3 in the N-terminal to C-terminal direction.
  • a “full-length light chain” or “light chain” is a polypeptide chain composed of a light chain variable region (VL) and a light chain constant region (CL) in the N-terminal to C-terminal direction.
  • the two pairs of full-length antibody chains are connected by a disulfide bond between CL and CH1 and a disulfide bond between the HR of the two full-length heavy chains.
  • the full-length antibody of the present invention can be from a single species, such as human; it can also be a chimeric antibody or a humanized antibody.
  • the full-length antibody of the present invention includes two antigen binding sites formed by a pair of VH and VL respectively, and the two antigen binding sites specifically recognize/bind the same antigen.
  • the term “Fd fragment” means an antibody fragment composed of VH and CH1 domains;
  • the term “dAb fragment” means an antibody fragment composed of VH domains (Ward et al., Nature 341:544 546 (1989));
  • the term “Fab fragment” means an antibody fragment composed of VL, VH, CL and CH1 domains;
  • the term “F(ab')2 fragment” means a fragment comprising a disulfide bridge connected by a hinge region The antibody fragment of two Fab fragments;
  • the term “Fab' fragment” means the fragment obtained by reducing the disulfide bond connecting the two heavy chain fragments in the F(ab')2 fragment, consisting of a complete light chain and heavy chain The Fd fragment (consisting of VH and CH1 domains) is composed.
  • Fv fragment means an antibody fragment composed of the VL and VH domains of a single arm of an antibody. Fv fragments are generally considered to be the smallest antibody fragments that can form a complete antigen binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a variable region (such as a Fd fragment, which contains only three CDRs specific to an antigen) can recognize and bind to an antigen, although its affinity may be lower than the complete binding site.
  • Fc fragment means that the second and third constant regions of the first heavy chain of an antibody are formed by disulfide bonding of the second and third constant regions of the second heavy chain. Antibody fragments. The Fc fragment of an antibody has many different functions, but does not participate in antigen binding.
  • scFv refers to a single polypeptide chain comprising VL and VH domains, wherein the VL and VH are connected by a linker (see, for example, Bird et al., Science 242:423 -426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)).
  • Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.
  • Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof.
  • GGGGS linker having an amino acid sequence
  • Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8: 725-731, Choi et al. (2001), Eur. J. Immunol.
  • di-scFv refers to an antibody fragment formed by linking two scFvs.
  • the term "diabody” means that its VH and VL domains are expressed on a single polypeptide chain, but a linker that is too short is used to allow it to be between the two domains of the same chain. Pairing, thereby forcing the domain to pair with the complementary domain of the other chain and create two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) ), and Poljak RJ et al., Structure 2:1121-1123 (1994)).
  • Each of the aforementioned antibody fragments maintains the ability to specifically bind to the same antigen that the full-length antibody binds, and/or competes with the full-length antibody for specific binding to the antigen.
  • bispecific antibody refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) or antibody analog through a coupling arm.
  • the coupling method includes but It is not limited to chemical reaction, gene fusion, protein fusion, polypeptide fusion and enzymatic.
  • Multispecific antibodies include, for example, trispecific antibodies and tetraspecific antibodies. The former is an antibody with three different antigen binding specificities, and the latter is an antibody with four different antigen binding specificities.
  • antibody mimetics refers to the same specific binding to an antigen as an antibody, but without the structure of an antibody. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.
  • DARPin and fynomer are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.
  • the designed ankyrin repeat protein (DARPin) is linked to IgG antibody, scFv-Fc antibody fragment or a combination thereof, such as CN104341529A.
  • the anti-IL-17a fynomer binds to the anti-IL-6R antibody, such as WO2015141862A1.
  • the technique for obtaining antibodies can use conventional techniques known to those skilled in the art (for example, recombinant DNA technology or enzymatic or chemical fragmentation methods) to obtain the antigen of the antibody from a given antibody (for example, the antibody provided by the present invention). Binding fragments (for example, the above-mentioned antibody fragments), and specifically screening for antigen-binding fragments of antibodies in the same manner as used for intact antibodies.
  • the terms “monoclonal antibody”, “monoclonal antibody”, and “mAb” have the same meaning and are used interchangeably, which refers to a group of highly homologous antibody molecules.
  • An antibody or a fragment of an antibody that is, a group of identical antibody molecules except for natural mutations that may occur spontaneously.
  • the monoclonal antibody has high specificity for a single epitope on the antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which usually include at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen.
  • the modifier "monoclonal” only indicates that the antibody is characterized as being obtained from a group of highly homologous antibodies, and cannot be understood as requiring any specific method to prepare the antibody.
  • the monoclonal antibody of the present invention can be prepared by a variety of techniques, such as hybridoma technology (see, for example, Kohler et al. Nature, 256:495,1975), recombinant DNA technology (see, for example, U.S. Patent Application 4,816,567), or phage Antibody library technology (see, for example, Clackson et al. Nature352:624-628, 1991, or Marks et al. J. Mol. Biol. 222:581-597, 1991).
  • monoclonal antibodies can be prepared as follows. First immunize mice or other suitable host animals with immunogen (add adjuvant when necessary).
  • the injection method of immunogen or adjuvant is usually subcutaneous multi-point injection or intraperitoneal injection.
  • the immunogen can be pre-conjugated to certain known proteins, such as serum albumin or soybean trypsin inhibitor, to enhance the immunogenicity of the antigen in the host.
  • the adjuvant may be Freund's adjuvant or MPL-TDM or the like. After the animal is immunized, the body will produce lymphocytes that secrete antibodies that specifically bind to the immunogen. In addition, lymphocytes can also be obtained by in vitro immunization.
  • hybridoma cells prepared above can be inoculated into a suitable culture medium for growth, and the culture medium preferably contains one or more substances capable of inhibiting the growth of unfused, parental myeloma cells.
  • HGPRT hypoxanthine guanine phosphotransferase
  • HAT medium hypoxanthine, aminopterin, and thymine
  • the preferred myeloma cells should have the characteristics of high fusion rate, stable antibody secretion ability, and sensitivity to HAT medium.
  • murine myeloma such as MOP-21 or MC-11 mouse tumor-derived strains (THE Salk Institute Cell Distribution Center, San Diego, Calif.
  • Methods for determining the binding specificity of monoclonal antibodies produced by hybridoma cells include, for example, immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunosorbent assay
  • the Scatchard assay described by Munson et al., Anal. Biochem. 107:220 (1980) can be used to determine the affinity of monoclonal antibodies.
  • the target cell line can pass the standards described in (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103, Academic Press, 1996). Dilution method for subcloning.
  • Suitable culture medium can be DMEM or RPMI-1640.
  • hybridoma cells can also grow in animals in the form of ascites tumors.
  • immunoglobulin purification methods such as protein A agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography, etc.
  • the monoclonal antibodies secreted by subclonal cells can be removed from the cell culture medium, Separated from ascites or serum.
  • Monoclonal antibodies can also be obtained through genetic engineering recombination technology. Using nucleic acid primers that specifically bind to the heavy and light chain genes of the monoclonal antibody for PCR amplification, DNA molecules encoding the heavy and light chain genes of the monoclonal antibody can be isolated from hybridoma cells. Insert the resulting DNA molecule into an expression vector, then transfect host cells (such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin), and culture them under appropriate conditions. Recombinantly expressed target antibodies can be obtained.
  • host cells such as E.coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin
  • Antibodies can be purified by known techniques, such as affinity chromatography using protein A or protein G. Subsequently or as an alternative, the specific antigen (the target molecule recognized by the antibody) or its epitope can be immobilized on a column, and the immunospecific antibody can be purified by immunoaffinity chromatography.
  • the purification of immunoglobulin can refer to, for example, D. Wilkinson (The Engineer, published by The Engineer, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).
  • murine antibody refers to the fusion of B cells derived from immunized mice with myeloma cells, followed by screening of mouse hybrid fusion cells that can proliferate indefinitely and secrete antibodies. Then proceed to screening, antibody preparation and antibody purification. Or, after the antigen invades the mouse body, B cells differentiate and proliferate to form plasma cells, which can produce and secrete antibodies. Stimulated by specific antigens, the production of antibodies is due to the interaction of various immune cells caused by antigens invading the human body, so that the B cells in the lymphocytes differentiate and proliferate to form plasma cells, which can produce and secrete antibodies.
  • chimeric antibody refers to an antibody whose light chain or/and part of its heavy chain is derived from an antibody (which can be derived from a specific species or belong to a certain species).
  • a specific antibody class or subclass), and another part of the light chain or/and heavy chain is derived from another antibody (which can be derived from the same or different species or belong to the same or different antibody class or subclass), but no matter However, it still retains the binding activity to the target antigen (USP 4,816,567 to Capability et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851 6855 (1984)).
  • chimeric antibody may include antibodies (e.g., human-mouse chimeric antibodies) in which the heavy and light chain variable regions of the antibody are derived from the first antibody (e.g., murine antibody), and the heavy chain and The light chain variable region is derived from a second antibody (e.g., a human antibody).
  • first antibody e.g., murine antibody
  • second antibody e.g., a human antibody
  • humanized antibody refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase homology with the sequence of a human antibody.
  • CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (for example, variable region FR and/or constant region) is derived from human source.
  • Immunoglobulin (receptor antibody) Humanized antibodies generally retain the expected properties of the donor antibody, including but not limited to antigen specificity, affinity, reactivity, ability to improve immune cell activity, and ability to enhance immune response.
  • the donor antibody can be a mouse, rat, rabbit, or non-human primate with expected properties (eg, antigen specificity, affinity, reactivity, ability to improve immune cell activity, and/or ability to enhance immune response) Animal-like (e.g., cynomolgus monkey) antibodies.
  • Humanized antibodies can not only retain the expected properties of non-human donor antibodies (such as murine antibodies), but also effectively reduce the immunogenicity of non-human donor antibodies (such as murine antibodies) in human subjects. Therefore, it is particularly advantageous.
  • the expected properties of the humanized antibody eg, antigen specificity, affinity, reactivity, ability to improve immune cell activity, and/or The ability to enhance immune response
  • a high degree of humanization for example, at least 75%, at least 80%, at least 85%, at least 90%, At least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% humanization degree
  • the framework region (FR) of the humanized antibody of the present invention may include both the amino acid residues of the human acceptor antibody and the corresponding non-human donor antibody.
  • the humanized antibody of the present invention can be prepared according to the sequence of the murine monoclonal antibody prepared above.
  • DNA encoding the heavy and light chains can be obtained from target murine hybridomas and engineered using standard molecular biology techniques to contain non-mouse (e.g., human) immunoglobulin sequences.
  • the murine immunoglobulin variable region can be linked to the human immunoglobulin constant region using methods known in the art (see, for example, U.S. Patent No. 4,816,567 to Cabilly et al.).
  • the DNA encoding VH is operably linked to another DNA molecule encoding the heavy chain constant region to obtain a full-length heavy chain gene.
  • the sequence of the human heavy chain constant region gene is known in the art (see, for example, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the heavy chain constant region may be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region, but is generally preferably an IgG1 or IgG4 constant region.
  • the DNA encoding VL is operably linked to another DNA molecule encoding the light chain constant region CL to obtain the full-length light chain gene (and the Fab light chain gene).
  • the sequence of the human light chain constant region gene is known in the art (see, for example, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242 ), DNA fragments containing these regions can be obtained by standard PCR amplification.
  • the light chain constant region can be a kappa or lambda constant region, but is generally preferably a kappa constant region.
  • transgenic animals can also be used, which can produce no endogenous immunoglobulin after immunization and can produce a complete human antibody library.
  • JH antibody heavy chain joining region
  • Non-limiting examples of the above-mentioned transgenic animals include HuMAb mice (Medarex, Inc.), which contain human immunoglobulin genes encoding unrearranged human heavy chain ( ⁇ and ⁇ ) and ⁇ light chain immunoglobulin sequences. Locus (miniloci), plus targeted mutations that inactivate endogenous mu and ⁇ chain loci (see, for example, Lonberg et al. (1994) Nature 368(6474):856-859); or carrying human heavy chain transgenes and humans The light chain transchromosome "KM MouseTM” (see patent application WO02/43478). Other methods for humanization of antibodies also include phage display technology (Hoogenboom et al., 1991, J. Mol. Biol. 227: 381; Marks et al., J. Mol. Biol. 1991, 222: 581-597; Vaughan et al., 1996 , Nature Biotech 14: 309).
  • degree of humanization is an index used to evaluate the number of non-human amino acid residues in a humanized antibody.
  • the degree of humanization of a humanized antibody can be predicted by the IMGT website DomainGapAlign to predict the homology of the variable region sequence with the human V domain.
  • homologous antibody refers to a variant of an antibody, which contains the same amino acid sequence as the amino acid sequence of the antibody or antigen-binding fragment thereof provided herein. Source, and wherein the variant retains the desired functional properties of the anti-CLDN18.2 antibody of the present invention.
  • the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed.
  • the strength or affinity of a specific binding interaction can be expressed by the equilibrium dissociation constant (KD) or the half maximum effect concentration (EC50) of the interaction.
  • the specific binding properties between two molecules can be determined using methods known in the art.
  • One method involves measuring the rate of antigen binding site/antigen complex formation and dissociation.
  • Both the "binding rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and the actual rate of association and dissociation (see Malmqvist M, Nature, 1993, 361 :186-187).
  • the ratio of kdis/kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473). Any effective method can be used to measure KD, kon and kdis values.
  • bioluminescence interferometry e.g., ForteBio's Octet method
  • surface plasmon resonance technology such as Biacore
  • Kinexa can also be used to measure the dissociation constant.
  • identity is used to refer to the matching of sequences between two polypeptides or between two nucleic acids.
  • a certain position in the two sequences to be compared is occupied by the same base or amino acid monomer subunit (for example, a certain position in each of the two DNA molecules is occupied by adenine, or two A certain position in each of the polypeptides is occupied by lysine)
  • the molecules are the same at that position.
  • the "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions to be compared ⁇ 100. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% identity.
  • the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of 6 positions match).
  • the comparison is made when two sequences are aligned to produce maximum identity.
  • Such alignment can be achieved by using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453 which can be conveniently performed by a computer program such as the Align program (DNAstar, Inc.). You can also use the algorithms of E. Meyers and W. Miller (Comput.
  • conservative substitution means an amino acid substitution that does not adversely affect or change the expected properties of a protein/polypeptide comprising an amino acid sequence.
  • a variant of an antibody obtained by conservatively substituting amino acids retains its source sequence.
  • Biological activity such as specifically binding to CLDN 18.2.
  • conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions of amino acid residues with similar side chains, such as those that are physically or functionally similar to the corresponding amino acid residues (e.g., have similar size, shape, charge, chemical properties, including The ability to form covalent bonds or hydrogen bonds, etc.) is replaced by residues.
  • Families of amino acid residues with similar side chains have been defined in the art. These families include basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamate), uncharged polar side chains (e.g., glycine , Asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g.
  • alanine, valine, leucine, isoleucine Acid, proline, phenylalanine, methionine), beta branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, Phenylalanine, tryptophan, histidine) amino acids. Therefore, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of amino acids are well known in the art (see, for example, Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999) ; And Burks et al. Proc. Natl Acad. Set USA 94:412-417 (1997), which is incorporated herein by reference).
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient, It is well-known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes but is not limited to: pH regulators, surfactants, adjuvants, ionic strength enhancement Agents, diluents, agents for maintaining osmotic pressure, agents for delaying absorption, preservatives.
  • pH adjusting agents include, but are not limited to, phosphate buffer.
  • Surfactants include but are not limited to cationic, anionic or nonionic surfactants, such as Tween-80.
  • Ionic strength enhancers include, but are not limited to, sodium chloride.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid and the like.
  • Agents for maintaining osmotic pressure include, but are not limited to, sugar, NaCl and the like.
  • Agents that delay absorption include, but are not limited to, monostearate and gelatin.
  • Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol) and the like.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, paraben, chlorobutanol, phenol, sorbic acid and the like.
  • Stabilizers have the meaning commonly understood by those skilled in the art, which can stabilize the desired activity of the active ingredients in the drug, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose) , Lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation products (such as lactalbumin hydrolysate).
  • prevention refers to a method performed in order to prevent or delay the occurrence of a disease or disorder or symptom (e.g., tumor, infection, or autoimmune disease) in a subject.
  • a disease or disorder or symptom e.g., tumor, infection, or autoimmune disease
  • treatment refers to a method performed in order to obtain beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, alleviating symptoms, narrowing the scope of the disease, stabilizing (ie, no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the disease Status, and relief of symptoms (whether partial or full), whether detectable or undetectable.
  • treatment can also refer to prolonging survival compared to expected survival (if not receiving treatment).
  • the term "subject” refers to a mammal, such as a primate mammal, such as a human.
  • the subject e.g., human
  • the subject has tumors, infections, or autoimmune diseases, or is at risk of suffering from the aforementioned diseases.
  • an effective amount refers to an amount sufficient to obtain or at least partially obtain the desired effect.
  • an effective amount for preventing a disease e.g., tumor, infection, or autoimmune disease
  • an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in patients who have already suffered from the disease. It is completely within the abilities of those skilled in the art to determine such an effective amount.
  • an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient’s own immune system, the patient’s general conditions such as age, weight and sex, the way the drug is administered, and other treatments administered simultaneously and many more.
  • immune cell includes cells that have hematopoietic origin and play a role in an immune response, such as lymphocytes, such as B cells and T cells; natural killer cells; myeloid cells, such as monocytes , Macrophages, eosinophils, mast cells, basophils and granulocytes.
  • the term "immune response” refers to immune cells (such as lymphocytes, antigen-presenting cells, phagocytes or granulocytes) and soluble macromolecules (including antibodies, cytokines) produced by immune cells or the liver. , And complement), which results in the selective damage, destruction or destruction of invasive pathogens, cells or tissues infected by pathogens, cancer cells, or normal human cells or tissues under autoimmune or pathological inflammation Cleared from the human body.
  • the term "antigen-specific T cell response” refers to an immune response produced by a T cell, and the response is generated when the T cell specific antigen stimulates the T cell.
  • Non-limiting examples of the response produced by T cells upon antigen-specific stimulation include the proliferation of T cells and the production of cytokines such as IL-2.
  • effector function refers to those biological activities attributable to the Fc region (natural sequence Fc region or amino acid sequence variant Fc region) of an antibody, and which vary with the antibody The same type varies.
  • antibody effector functions include, but are not limited to: Fc receptor binding affinity, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) , Down-regulation of cell surface receptors (such as B cell receptors), B cell activation, cytokine secretion, half-life/clearance of antibodies and antigen-antibody complexes, etc.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • Down-regulation of cell surface receptors such as B cell receptors
  • B cell activation such as B cell activation
  • cytokine secretion half-life/clearance of antibodies and antigen-antibody complexes, etc.
  • cancer and “tumor” are used interchangeably and refer to a large group of diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division may lead to the formation of malignant tumors or cells that invade adjacent tissues, and may metastasize to distant parts of the body through the lymphatic system or bloodstream. Cancers include benign and malignant cancers as well as dormant tumors or micrometastasis. Cancer also includes hematological tumors, especially hematological malignancies.
  • lymphoma includes lymphoma, leukemia, myeloma or lymphoid malignancies, as well as spleen cancer and lymph node tumors.
  • exemplary lymphomas include B-cell lymphoma and T-cell lymphoma.
  • B-cell lymphoma including, for example, Hodgkin's lymphoma.
  • T-cell lymphoma including, for example, cutaneous T-cell lymphoma.
  • Hematological malignancies also include leukemias, such as secondary leukemia or acute lymphocytic leukemia.
  • myeloma eg, multiple myeloma
  • other hematological and/or B cell or T cell related cancers include myeloma (eg, multiple myeloma) and other hematological and/or B cell or T cell related cancers.
  • the term "pharmaceutically acceptable” means that when the molecular body, molecular fragment or composition is properly administered to animals or humans, they will not produce adverse, allergic or other adverse reactions.
  • Specific examples of substances that can be used as pharmaceutically acceptable carriers or components thereof include sugars (such as lactose), starch, cellulose and its derivatives, vegetable oils, gelatin, polyols (such as propylene glycol), alginic acid, and the like.
  • the combination therapy includes combining the antibody-drug conjugate, composition or pharmaceutical composition of the present invention with one or more therapeutic agents (e.g., chemotherapeutics) or other prevention or treatment modes (e.g., , Radiotherapy) combined use.
  • therapeutic agents e.g., chemotherapeutics
  • other prevention or treatment modes e.g., Radiotherapy
  • Exemplary therapeutic agents for the second therapy may include chemotherapeutic agents (e.g., mitotic inhibitors), alkylating agents (e.g., Nitrogen Mustard), antimetabolites (e.g., folate analogs), natural products (e.g., Vinca alkaloid Vinca Alkaloid), various reagents (such as platinum coordination complexes), hormones and antagonists (such as adrenal corticosteroids), immunomodulators (such as Bropirimine, Upjohn), etc.
  • chemotherapeutic agents e.g., mitotic inhibitors
  • alkylating agents e.g., Nitrogen Mustard
  • antimetabolites e.g., folate analogs
  • natural products e.g., Vinca alkaloid Vinca Alkaloid
  • various reagents such as platinum coordination complexes
  • hormones and antagonists such as adrenal corticosteroids
  • immunomodulators such as Bropirimine, Upjohn
  • Combination therapies include therapeutic agents that affect the immune response (e.g., enhance or activate the response) and therapeutic agents that affect (e.g., inhibit or kill) tumor/cancer cells.
  • Combination therapy can reduce the possibility of drug-resistant cancer cells.
  • Combination therapy may allow the dose of one or more of the agents to be reduced to reduce or eliminate the adverse effects associated with one or more of the agents.
  • Such combination therapies can have a synergistic therapeutic or preventive effect on underlying diseases, disorders or conditions.
  • “combination” includes therapies that can be administered separately, for example, separately formulated for separate administration (for example, can be provided in a kit), and therapies that can be administered together as a single formulation (ie, "co-formulation") .
  • the antibody-drug conjugate, composition or pharmaceutical composition of the present invention can be administered sequentially.
  • the antibody-drug conjugate, composition or pharmaceutical composition may be administered simultaneously.
  • the antibody-drug conjugate of the present invention can be used in any combination with at least one other (active) agent.
  • HER2 negative refers to the absence of a large amount of HER2 protein on the cell surface, including IHC 1+, or IHC 2+/FISH negative, as well as IHC 0 to 1+ and IHC 1+ to 2+.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • C 1-6 alkyl means a straight-chain or branched alkyl group containing 1-6 carbon atoms, including, for example, "C 1-4 alkyl” and "C 1-3 alkyl” Etc. Specific examples include but are not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methyl Butyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl Base, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl Group, 2-
  • C 1-6 alkylene refers to a divalent group obtained by losing two hydrogen atoms of a straight or branched chain alkane containing 1-6 carbon atoms, including, for example, “C 1-4 alkylene “Group”, “C 1-3 alkylene” and the like, specific examples include but are not limited to: methylene, ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene Base or 1,6-hexylene, etc.
  • C 2-10 alkenyl refers to a straight-chain or branched alkenyl group having at least one double bond and a carbon number of 2-10, including, for example, “C 2-6 alkenyl”, “ C 2-4 alkenyl” and so on.
  • Examples include but are not limited to: vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl Alkenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexenyl Dienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, 1,4-cyclohexadienyl, etc.
  • C 2-10 alkenylene refers to a divalent group obtained by losing two hydrogen atoms in an olefin containing 2-10 carbon atoms. Including, for example, “C 2-8 alkenylene”, “C 4-6 alkenylene” and the like. Examples thereof include, but are not limited to: 1,5-pentenylene, 1,5-penten-2-enyl, 1,6-hexenylene, and the like.
  • C 2-10 alkynyl refers to a straight-chain or branched alkynyl group having at least one triple bond and a carbon number of 2-10, including, for example, “C 2-6 alkynyl", “ C 2-4 alkynyl” and so on. Examples include but are not limited to: ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3 -Hexynyl, 5-methyl-2-hexynyl, etc.
  • C 2-10 alkynylene refers to a divalent group obtained by losing two hydrogen atoms of an alkyne containing 2-10 carbon atoms. Including, for example, “C 2-8 alkynylene", “C 4-6 alkynylene” and the like. Examples thereof include, but are not limited to: 1,5-pentynylene, 1,5-pentynylene-2-ynyl, 1,6-hexynylene, and the like.
  • C 1-6 alkoxy refers to a group having a structure of C 1-6 alkyl-O-, wherein C 1-6 alkyl is as defined above. Specific examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy Group, hexyloxy group, etc.
  • the term "5-12 membered heteroaryl” refers to an aromatic cyclic group containing 5-12 ring members, and at least one of the ring members is a heteroatom selected from N, O, and S. Specific examples include, but are not limited to, 5-10 membered heteroaryl, 5-10 membered nitrogen-containing heteroaryl, 5-6 membered oxygen-containing heteroaryl, etc., such as furyl, thienyl, pyrrolyl, thiazolyl, isothiazole Group, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1, 2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyrida
  • the present invention is not limited to the specific methodologies, protocols, cell lines, vectors, or reagents described herein, as they can vary.
  • the terms used herein are only used for the purpose of describing specific embodiments, not for limiting the scope of the present invention.
  • Figure 1A shows the flow cytometric detection of HEK293T-Claudin 18.2 monoclonal stable cell line.
  • Figure 1B shows the flow cytometric assay of L929-Claudin 18.2 monoclonal stable cell line.
  • Figure 1C shows the flow cytometric detection of KATOIII-Claudin 18.2 monoclonal stable cell line.
  • Figure 1D shows the flow cytometric detection of NCI-N87-Claudin 18.2 monoclonal stable cell line.
  • Figure 1E shows the Western blot detection of HEK293T-Claudin 18.1 monoclonal stable cell line.
  • Figure 2 shows 2C6.9-hz21, IMAB362 antibody affinity detection (flow cytometry).
  • Figure 3 shows the 2C6.9-hz21, IMAB362 antibody affinity detection (L929-Claudin 18.2 cells).
  • Figure 4 shows the specificity of 2C6.9-hz21 antibody detected by flow cytometry.
  • Figure 5 shows the CDC killing activity of 2C6.9-hz21 and IMAB362 on HEK293T-Claudin 18.2 cells.
  • Figure 6 shows the detection of ADCC activity of 2C6.9-hz21 and IMAB362 antibodies (HEK293T-Claudin 18.2 cells).
  • Figure 7 shows the HPLC-SEC detection profile of 2C6.9-TL001 (DAR: 3.79).
  • Figure 8 shows the HPLC-SEC detection profile of 2C6.9-TL001 (DAR: 7.12).
  • Figure 9 shows the test results of the affinity between 2C6.9-TL001 (DAR: 7.12) and Claudin 18.2 on the cell membrane surface.
  • Figure 10A shows the detection result of 2C6.9-TL001 (DAR: 7.12) on the killing activity of HEK293T-Claudin 18.2 cells.
  • Figure 10B shows the detection result of 2C6.9-TL001 (DAR: 3.79) on the killing activity of HEK293T-Claudin 18.2 cells.
  • Figure 10C shows the detection result of 2C6.9-TL001 (DAR: 7.12) on the killing activity of HEK293T-Claudin 18.1 cells.
  • Figure 10D shows the detection results of 2C6.9-TL002 and 2C6.9-TL003 on HEK293T-Claudin 18.2 cell killing activity.
  • Figure 10E shows the detection results of 2C6.9-TL002 and 2C6.9-TL003 on HEK293T-Claudin 18.1 cell killing activity.
  • Figure 11A shows the results of the detection of 2C6.9-TL001 (DAR: 7.12) on the killing activity of NUGC-4 cells.
  • Figure 11B shows the results of the detection of the killing activity of 2C6.9-TL001 (DAR: 3.79) on NUGC-4 cells.
  • Figure 11C shows the detection results of 2C6.9-TL002 and 2C6.9-TL003 on the killing activity of NUGC-4 cells.
  • Figure 12A shows the change of tumor volume in each group of mice in the subcutaneous NCI-N87-Claudin18.2 cell transplantation tumor model of Balb/c Nude mice (*: P ⁇ 0.05; ****: P ⁇ 0.0001).
  • Figure 12B shows the changes in body weight of mice in each group in the Balb/c Nude mouse subcutaneous NCI-N87-Claudin18.2 cell transplantation tumor model.
  • Figure 12C shows the results of comparing the efficacy of 2C6.9-TL001 and 2C6.9 mAb + chemotherapy in the CDX model for 11 days in vivo (****: P ⁇ 0.0001).
  • Figure 12D shows the comparison of the efficacy of 2C6.9-TL001 and 2C6.9 mAb+chemotherapy in the 21-day CDX model (****: P ⁇ 0.0001).
  • Figure 12E shows the change of tumor volume in each group of mice in the CDX (NUGC-4) model with different DAR values of 2C6.9-TL001 on 21 days (****: P ⁇ 0.001).
  • Figure 12F shows the changes in the body weight of mice in each group for 21 days in the CDX (NUGC-4) model with different DAR values of 2C6.9-TL001.
  • Figure 12G shows the Balb/c Nude mouse subcutaneously Changes in tumor volume of mice in each group in the gastric cancer GA0006 PDX model at 17 days (****: P ⁇ 0.0001).
  • Figure 12H shows the Balb/c Nude mouse subcutaneously Changes in body weight of mice in each group in 17 days of gastric cancer GA0006 PDX model.
  • Figure 12I shows the Balb/c Nude mouse subcutaneously Changes in tumor volume of mice in each group in 24 days in the GA0006 PDX model of gastric cancer (****: P ⁇ 0.0001).
  • Figure 12J shows the Balb/c Nude mouse subcutaneously Changes in body weight of mice in each group in 24 days in the GA0006 PDX model of gastric cancer.
  • Figure 12K shows the change of tumor volume in each group of mice in the subcutaneous NCI-N87-Claudin18.2 cell transplantation tumor model of Balb/c Nude mice (***: P ⁇ 0.001; ****: P ⁇ 0.0001) .
  • Figure 12L shows the changes in body weight of mice in each group in the Balb/c Nude mouse subcutaneous NCI-N87-Claudin18.2 cell transplantation tumor model.
  • Figure 12M shows the change of tumor volume in each group of mice in the subcutaneous HEK293T-Claudin18.2 cell transplantation tumor model of Balb/c Nude mice (**: P ⁇ 0.01; ****: P ⁇ 0.0001).
  • Figure 12N shows the changes in body weight of mice in each group in the subcutaneous HEK293T-Claudin18.2 cell transplantation tumor model of Balb/c Nude mice.
  • Figure 120 shows the changes in tumor volume of each group of mice in the Balb/c Nude mouse subcutaneous NUGC-4 cell transplantation tumor model (****: P ⁇ 0.0001).
  • Figure 12P shows the changes in body weight of mice in each group in the Balb/c Nude mouse subcutaneous NUGC-4 cell transplantation tumor model.
  • Figure 13 shows the HPLC-SEC detection profile of 2C6.9-TL001 (DAR: 7.40).
  • Methanesulfonyl chloride (462mg, 12.77mmol, purity about 70%) was added dropwise to a solution of belotecan hydrochloride (3g, 6.38mmol) and triethylamine (2.58g, 25.54mmol) in dichloromethane (40mL) at room temperature Under the conditions, the reaction is 2h.
  • compound 3-2 (200mg, 0.8mmol) was dissolved in a mixed solution of tetrahydrofuran and water (4mL/4mL), lithium hydroxide monohydrate (235mg, 5.6mmol) was added, the reaction was stirred at room temperature for 4h, diluted with water, Extract with ethyl acetate (20mL ⁇ 2), adjust the pH to 3 with 1N hydrochloric acid for the aqueous phase, extract with ethyl acetate (20mL ⁇ 3), combine the organic phases, wash with saturated brine (20mL ⁇ 2), and dry with anhydrous sodium sulfate. The desiccant was filtered off, and the solvent was evaporated under reduced pressure to obtain 120 mg of the title compound.
  • Step 1 Synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(propargyl)hex-5-ynamide (Compound 3-5)
  • Step 2 (4-((S)-35-azido-2-(4-(((4-methoxyphenyl) benzhydryl)amino)butyl)-4,8-diox ((S)-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazatripentacoylamino)benzyl)((S)-4-ethyl -11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4 ': Synthesis of 6,7] indazino[1,2-b]quinolin-4-yl)carbonate (Compound 33-1)
  • Step 3 ((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetra Hydrogen-1H-pyrano[3',4':6,7]indazino[1,2-b]quinolin-4-yl)(4-((S)-2-(4-(( (4-Methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-yne Amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonane Synthesis of oxy-3,9-diaza pentapentadecyl amido)benzyl)carbonate (compound 33-2
  • Step 4 (4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-yne Amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-Nine Oxa-3,9-diaza pentapentadecylamido)benzyl)((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl) -3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]inazino[1,2-b]quinoline-4 -Base) carbonate (compound TL001) synthesis
  • Step 1 (S)-(4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyran[3',4': Synthesis of 6,7] indazino[1,2-b]quinolin-9-yl)(4-nitrophenyl) carbonate
  • Step 2 (S)-tert-butyl (4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyran [3', Synthesis of 4':6,7] indazino[1,2-b]quinolin-9-yl)ethane-1,2-diyl bis(methyl carbamate)
  • Step 3 (S)-N-methyl-(4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyran [3 Synthesis of',4':6,7]indazino[1,2-b]quinolin-9-yl)(2-(methylamino)ethyl)carbamate trifluoroacetate
  • Step 4 (4-((S)-2-((S)-2-(4-(1-(26-azide-3,6,9,12,15,18,21,24-octaoxy Heterohexadecyl)piperidin-4-yl)butyramido)-3-methylbutyramido)propionamido)benzyl)((S)-4,11-diethyl-4-hydroxyl -3,14-dioxo-3,4,12,14-tetrahydro-1H-pyran[3',4':6,7]inazino[1,2-b]quinoline-9- Synthesis of ethane-1,2-diyl bis(methyl carbamate)
  • Mobile phase A acetonitrile
  • mobile phase B water (0.05% formic acid)
  • Step 5 ((S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyran[3',4': 6,7]Indazino[1,2-b]quinolin-9-yl)(4-((S)-2-((S)-3-methyl-2-(4-(1-( 26-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamido)methyl)-1H-1,2,3-triazol-1-yl )-3,6,9,12,15,18,21,24-octaoxahexadecyl)piperidin-4-yl)butyramido)butyramido)propionamido)benzyl)ethyl Synthesis of Alkyl-1,2-Diyl Bis(Methyl Carbamate) Trifluoroacetate
  • the reaction solution was purified by preparative high performance liquid chromatography.
  • the preparation solution was lyophilized and dissolved in dichloromethane (2mL), added with trifluoroacetic acid (0.2mL), and stirred at 25°C for 0.5h. Purified by preparative high performance liquid chromatography, the preparation solution was freeze-dried to obtain 16 mg of the title compound.
  • Mobile phase A acetonitrile
  • mobile phase B water (0.05% trifluoroacetic acid)
  • Mobile phase A acetonitrile
  • mobile phase B water
  • Step 2 4-(4-((S)-1-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropyl-2-yl)amino) Synthesis of tert-butyl -3-methyl-1-oxobutyl-2-yl)amino)-4-oxobutyl)piperidine-1-carboxylate
  • Step 3 (S)-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropyl-2-yl)-3-methyl-2- Synthesis of (4-(piperidin-4-yl)butyramido)butyramide trifluoroacetate
  • reaction solution was concentrated under reduced pressure, the residue was dissolved in acetonitrile (30 mL), potassium carbonate (1.22 g, 8.85 mmol) was added, and the reaction was carried out at 25° C. for 2 h. Suction filtration, the filter cake was washed with acetonitrile, the filtrate was collected, and concentrated under reduced pressure to obtain 900 mg of the title compound.
  • Step 4 (S)-2-(4-(1-(26-azido-3,6,9,12,15,18,21,24-octaoxahexadecyl)piperidine- 4-yl)butyramido)-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropyl-2-yl)-3-methylbutan Synthesis of amide
  • Step 5 (4-((S)-2-((S)-2-(4-(1-(26-azide-3,6,9,12,15,18,21,24-octaoxy Synthesis of Heterohexadecyl)piperidin-4-yl)butyramido)-3-methylbutyramido)propionamido)benzyl)(4-nitrophenyl)carbonate
  • Step 6 (4-((S)-2-((S)-2-(4-(1-(26-azide-3,6,9,12,15,18,21,24-octaoxy Heterohexadecyl)piperidin-4-yl)butyramido)-3-methylbutyramido)propionamido)benzyl)2-((S)-4-ethyl-4-hydroxy- 3,14-Dioxo-3,4,12,14-tetrahydro-1H-pyran[3',4':6,7]inazino[1,2-b]quinolin-11-yl) Synthesis of ethyl isopropyl carbamate
  • Step 7 (4-((S)-2-((S)-3-methyl-2-(4-(1-(26-(4-((6-(2-(methylsulfonyl) (Pyrimidine-5-yl)hex-5-ynyl amido)methyl)-1H-1,2,3-triazol-1-yl)-3,6,9,12,15,18,21,24 -Octaoxahexadecyl)piperidin-4-yl)butyramido)butyramido)propionamido)benzyl)2-((S)-4-ethyl-4-hydroxy-3, 14-Dioxy-3,4,12,14-tetrahydro-1H-pyran[3',4':6,7]inazino[1,2-b]quinolin-11-yl)ethyl Synthesis of Isopropyl Carbamate Trifluoroacetate
  • Mobile phase A acetonitrile
  • mobile phase B water (0.05% trifluoroacetic acid)
  • the human Claudin 18.2 monoclonal antibody in the present invention is a humanized monoclonal antibody, including 2C6.9-hz11 and 2C6.9-hz21.
  • the CDR, variable region sequence and constant region sequence information are shown in Table 1:
  • Table 1 Summary table of sequence information
  • the human Claudin 18.2 complete coding sequence (gene number: NM_001002026.2, synthesized by Nanjing GenScript Biotechnology Co., Ltd.) and the human Claudin 18.1 complete coding sequence (gene number: NM_016369) .3, synthesized by Nanjing GenScript Biotechnology Co., Ltd.) cloned into the lentiviral vector pLVX-IRES-puro, and passed the literature (Mohammadi Z etl., Mol Biotechnol.
  • Lentiviral packaging system prepares the virus, and after the virus is obtained, the HEK293T, L929, KATOIII and NCI-N87 cells are respectively infected, and the monoclonal HEK293T-Claudin 18.1, HEK293T-Claudin 18.2, L929 are obtained through puromycin screening and monoclonal selection.
  • the human Claudin 18.2 and human Claudin 18.1 plasmids were transfected into BaF/3 cells (DSMZ, Cat#ACC300) using the 4D-Nucleofector X Transfection Kit (Lonza, Cat#V4XC-3012), and 1.25 mg/ mL hygromycin (Thermo Fisher Sci.Cat# 10687010) was screened. After 12 days of screening, single clones were sorted to obtain monoclonal BaF/3-Claud 18.1 and BaF/3-Claud 18.2 cell lines.
  • HEK293T-Claudin 18.1 uses Western Blot identification (detection antibody: Proteintech, 66167-1-Ig), other cell lines use flow cytometry (flow cytometer: Beckman, CytoFlex; detection antibody IMAB362, sequence from patent: CN 101312989B ) For identification. As shown in Figures 1A-1D, the flow cytometry results show that HEK293T-Claudin 18.2, L929-Claudin 18.2, KATOIII-Claudin 18.2, and NCI-N87-Claudin 18.2 all have a high positive rate (close to 100%) and good uniformity. Monoclonal cell line can be used for subsequent experiments.
  • the invention uses DNA immunization and cellular immunization to immunize wild-type mice to obtain anti-human Claudin 18.2 murine monoclonal antibodies.
  • Each Balb/c mouse was injected with 100 ⁇ g plasmid containing the complete coding sequence of human Claudin 18.2 by way of tail vein injection.
  • the serum titer was detected by flow cytometry.
  • the mice with higher titer were selected for booster immunization with BaF/3-Claudin18.2 overexpression cell line 3-5 days before fusion.
  • the standard fusion process was used to fuse mouse spleen cells with Sp2/0 (ATCC, Cat#CRL-1581) mouse myeloma cell line using PEG fusion, and then HAT pressure screening was performed, and flow was performed 10-14 days later. ⁇ filtering.
  • the human gastric cancer cell line NUGC4 (purchased from the Japanese JCRB cell bank, catalog number: JCRB0834) endogenously expresses Claudin 18.2 protein, and is widely used to detect the binding of antibodies to endogenous Claudin 18.2 and develop functional detection methods. NUGC4 cells were used to detect candidate clones, and finally 7 subclones were selected as candidate clones. After further affinity detection, 2C6.9M was selected for variable region amplification and humanization.
  • the Pierce Rapid Isotyping kit (Thermo Fisher Sci.Cat#26179) was used to identify 2C6.9M. The identification results showed that the heavy chain was of IgG1 subtype, and the light chain was of Kappa subtype.
  • the number of hybridoma cells was cultured to about 8000, the cells were lysed and the first strand cDNA was synthesized using a cDNA reverse transcription kit (Thermo Fisher Sci. Cat# 18080-200).
  • the primers were used to amplify VH and VK (VL Kappa) genes from cDNA.
  • the PCR products were purified by DNA purification kit (Qiagen, Cat#28104) and ligated to TOPO vector (Thermo Fisher Sci.Cat#K457540). Approximately 12 clones were picked for each ligation reaction and sequenced. The sequence was analyzed by Vector NTI 11.5 (Thermo Fisher Sci.) and Sequencer 5.4.6 (Genecodes). The obtained murine antibody 2C6.9M variable region sequence and CDR sequence are shown in Table 2.
  • the mouse antibody 2C6.9M was humanized by the CDR grafted antibody humanization method.
  • the humanization transformation involves the following steps: compare the amino acid sequence of the mouse monoclonal antibody with the amino acid sequence of the human germline antibody to find a sequence with high homology and superior physical and chemical properties, and use it as a human embryonic line. Framework sequence; analyze and investigate HLA-DR affinity, select the human embryonic framework sequence with low affinity; then transplant the six CDRs of the mouse antibody to the selected heavy chain and light chain framework sequences.
  • the heavy chain and light chain CDR regions of the murine antibody 2C6.9M were respectively grafted onto the FR framework of the corresponding humanized template.
  • the humanized heavy chain and light chain templates of 2C6.9M are human germline gene sequences IGHV4-59*01 (see IMGT accession number AB019438) and IGKV4-1*01 (see IMGT accession number Z00023), respectively.
  • variable region sequence of the murine antibody 2C6.9M is shown in SEQ ID NO: 23 and SEQ ID NO: 24, and its CDR sequence is shown in SEQ ID NO: 1 to SEQ ID NO: 12.
  • the present invention modified the 2C6.9 CDR-H2 amino acid sequence, and the modified sequence is shown in SEQ ID NO: 21 and SEQ ID NO: 22.
  • two humanized antibodies were constructed, named 2C6.9-hz11 and 2C6.9-hz21.
  • the heavy chain constant region of each antibody is a human wild-type IgG1 heavy chain constant region (SEQ ID NO: 16), and the light chain constant region of the antibody is a human wild-type IgG1 kappa light chain constant region (SEQ ID NO: 17).
  • variable region, constant region, and heavy and light chain amino acid sequences of each antibody are shown in Table 1.
  • the heavy chain and light chain amino acid sequences of the 2C6.9 humanized antibody are linked into the plasmid pcDNA3.4 through codon optimization synthesis cDNA (entrusted to Nanjing GenScript Biotechnology Co., Ltd.).
  • the pcDNA3.4 corresponding to the heavy chain and light chain were simultaneously transfected into Expi293F cells (purchased from Thermo), and the supernatant after the cell culture was purified by protein A (MabSelect SuRe, GE) affinity chromatography column to obtain 2C6 .9 humanized monoclonal antibody.
  • HEK293T-Claudin 18.2 cells were used to detect the affinity of 2C6.9-hz21 with human Claudin 18.2 on the cell membrane.
  • the specific steps are as follows: digest HEK293T-Claudin18.2 cells, centrifuge and resuspend, wash twice with PBS; resuspend the cells with PBS (containing 1% BSA), pour 300,000 cells/well into 96-well tip bottom plate, 50 ⁇ l per well Pave 20 wells; add 50 ⁇ L 2C6.9-hz21 and IMAB362 antibodies to each well.
  • the final concentration starts at 1000nM and is diluted by 3 times.
  • Antibody name EC50(nM) Max MFI 2C6.9-hz21 5.767 165866.3 IMAB362 8.217 156715.7
  • Human Claudin 18.2 is a four-time transmembrane membrane protein with a complex structure.
  • Cell ELISA is used for detection to ensure the complete configuration of the Claudin 18.2 antigen molecule.
  • the L929-Claudin 18.2 stable cell line constructed in 6.1 was selected for detection.
  • Antibody name EC50(nM) Maximum signal value (OD450) 2C6.9-hz21 0.12 0.92 IMAB362 0.15 0.53
  • the present invention also detects the specificity of the candidate antibody through flow cytometry.
  • the specific steps are as follows: digest HEK293T, HEK293T-human Claudin 18.1, HEK293T-human Claudin 18.2 cells, centrifuge and resuspend, and wash twice with PBS; resuspend the cells with PBS (containing 1% BSA), each of which takes 300,000 cells Add candidate antibody with a final concentration of 1000nM, mix well, and react for 1 hour at 4°C in the dark; wash 3 times with PBS, add FITC-labeled anti-human Fc secondary antibody (brand: BioLegend, catalog number: 409322), and incubate at 4°C in the dark for 0.5 Hour; PBS wash 3 times, flow cytometry (flow cytometer brand: Beckman, model: Cytoflex) detection.
  • 2C6.9 is an IgG1 subtype, which can effectively activate the classical pathway of complement and exert the complement dependent cytotoxicity (CDC) function.
  • CDC complement dependent cytotoxicity
  • the present invention uses guinea pig serum with rich complement content (purchased from Zhengzhou Beiji, product number: S0001) as the material for experiment.
  • the specific experimental steps are as follows: Take HEK293T-Claudin 18.2 cells, adjust the cell density after centrifugation, and plate 5 ⁇ 10 4 /well overnight; prepare DMEM+20% guinea pig serum medium on the second day, and use this medium to dilute 2C6.9-hz21 And IMAB362 antibody, starting at 20 ⁇ g/mL, 2 times dilution, 10 concentration points; remove the original culture medium of HEK293T-Claudin 18.2 cells, add the antibody diluted in the previous step to the corresponding well, 100 ⁇ L/well; set Completely kill the positive control group, that is, add 10 ⁇ l/well lysis buffer; after standing for 3 hours in a 37°C, 5% CO 2 incubator, add CellTiter-Glo Luminescent (CTG, purchased from Promega, catalog number: G7573) staining solution Stain, 50 ⁇ l/well, mix well for 30 seconds, place at room temperature for 1 minute, measure the fluorescence signal value with
  • Antibody name EC50 value (ng/mL) 2C6.9-hz21 1363 IMAB362 3317
  • ADCC antibody-dependent cellular cytotoxicity
  • 2C6.9 is an IgG1 subtype with strong antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • the specific experimental procedures are as follows: Take HEK293T-Claudin 18.2 cells, adjust the cell density after centrifugation, and plate 1 ⁇ 10 4 cells/well overnight; remove the medium from the plate the next day, take NK92MI-CD16a cells (Huabo Bio) and centrifuge with Resuspend in empty MEMA medium, adjust the cell density to 1 ⁇ 10 6 /mL, add 50 ⁇ l/well to the corresponding well; dilute 2C6.9-hz21 and IMAB362 antibody with empty MEMA medium, HEK293T-Claudin18.2 cells 40 ⁇ g/ ml start, 5-fold dilution, 10 concentration points; NUGC-4 cells start at 2mg/mL, 5-fold dilution, 11 concentration points; add 50 ⁇ L/well of diluted antibody to the corresponding well, put it at 37°C, After standing for 5.5 hours in a 5% CO 2 cell incubator, add lysis buffer to the positive control well, and after standing for another 0.5 hours, add lactate dehydr
  • Antibody name EC50 value (ng/mL) Maximum kill rate (%) 2C6.9-hz21 67.67 30 IMAB362 57.66 20
  • the TL001 prepared in Example 3 is coupled with the 2C6.9 humanized monoclonal antibody to prepare 2C6.9-TL001.
  • the preparation method is as follows:
  • Buffer replacement Use 30KDa 50ml ultrafiltration tube (Millipore) to replace 2C6.9-TL001 with 10mM histidine-histidine hydrochloride + 8% sucrose (pH6.0) buffer , The replacement factor is 15 times; collect samples, add 10% Tween-20 to make the final concentration of Tween-20 in the sample 0.02% (M/V).
  • Liquid chromatography column ThermoMAbPac RP 3.0*100mm;
  • Mobile phase B 0.1%FA/2%H2O/98%ACN
  • Switching valve 0-3min to waste, 3-22min to MS, 22-30min to waste
  • Mass spectrometer model AB Sciex Triple TOF 5600+;
  • the antibody light chain (LC) in 2C6.9-TL001 is coupled with 0 to 1 toxin (the ratio of LC and DAR1 are 57.8% and 42.2% respectively)
  • the heavy chain (HC) is coupled with 0 to 4 toxins (the proportions of HC, DAR1, DAR2, DAR3, and DAR4 are 22.5%, 30.3%, 25.0%, 21.9%, 0.3%, respectively), to calculate the coupling between the antibody and the toxin
  • the feeding ratio of TL001 and 2C6.9-hz21 is 9:1
  • the light chain of the antibody in 2C6.9-TL001 is coupled with 0 to 1 toxin (the ratio of LC and DAR1 is 7.5% and 92.5% respectively)
  • heavy chain Coupling 0 to 4 toxins the proportions of HC, DAR1, DAR2, DAR3, and DAR4 are 2.5%, 10.2%, 9.8%, 76.4%, 1.1%, respectively
  • the coupling ratio of antibody to toxin (DAR) is calculated as 7.12.
  • the coupling feed ratio is 9:1
  • the antibody light chain in 2C6.9-TL001 is coupled with 0 to 1 toxin (the ratio of LC, DAR1, respectively) 1.5%, 24.0%)
  • heavy chain coupled with 0 to 4 toxins the proportions of HC, DAR1, DAR2, DAR3, and DAR4 are 0.7%, 2.1%, 14.3%, 54.5%, 2.8%, respectively
  • the antibody to toxin coupling ratio (DAR) was 7.40.
  • the ADC molecular structure in 2C6.9-TL001 is as follows:
  • ⁇ is an integer from 1 to 10
  • A is 2C6.9-hz21.
  • the conjugate was detected by SEC-HPLC.
  • Liquid chromatography column TSKgel G3000SWxl, 300*7.8mm, 5 ⁇ m;
  • Injection volume 40 ⁇ l; isocratic operation: 30min.
  • the SEC chromatograms of 2C6.9-TL001 (DAR: 3.79) and 2C6.9-TL001 (DAR: 7.12) are shown in Figure 7-8, and the SEC chromatograms of 2C6.9-TL001 (DAR: 7.40) are shown in Figure 13
  • the molecular weight of the main coupling product is about 150kD, that is, the 2C6.9-TL001 obtained by coupling TL001 and 2C6.9-hz21 still maintains the intact structure of the antibody.
  • the TL002 and TL003 prepared in Example 4 and Example 5 were coupled with the humanized monoclonal antibody 2C6.9 using the same preparation method to prepare 2C6.9-TL002 and 2C6.9-TL003. Preparation and detection methods As mentioned above, the final DAR values of 2C6.9-TL002 and 2C6.9-TL003 are 6.95 and 7.03, respectively.
  • the ADC molecular structure in 2C6.9-TL002 is as follows:
  • ⁇ is an integer from 1 to 10
  • A is 2C6.9-hz21.
  • the ADC molecular structure in 2C6.9-TL003 is as follows:
  • ⁇ is an integer from 1 to 10
  • A is the 2C6.9 antibody.
  • the present invention uses a cell ELISA method to detect the affinity of 2C6.9-TL001 (DAR: 7.12) with Claudin 18.2 on the cell membrane surface.
  • the specific experimental steps are as follows: The adherent growth of the L929-Claudin 18.2 cell line was digested with 2mM EDTA, resuspended to 2*10 ⁇ 5 cells/ml, 100 ⁇ L per well was plated in a 96-well plate, and incubated overnight at 37°C; Remove the medium, wash once with PBS, add 100 ⁇ L 4% formaldehyde to each well for 30 minutes at room temperature, remove formaldehyde, wash twice with PBS, add 100 ⁇ L PBS (containing 2% BSA) to block for 2 hours; remove the blocking solution, use PBS (containing 2%BSA) diluted to be tested 2C6.9-TL001, 9.375 ⁇ g/mL starting, 4-fold dilution, 9 concentration points, 100 ⁇ L/well added to the well, 37°C for 2
  • HEK293T-Claudin 18.2 and HEK293T-Claudin 18.1 cells are selected to detect the killing activity of 2C6.9-TL001 on Claudin 18.2 high expression cell lines.
  • the specific experimental steps are as follows: the day before the experiment, the cells were diluted with DMEM+10% FBS, 100 ⁇ L/well, and 1*10 ⁇ 4 cells per well were plated overnight; the second day, the ADC molecules were diluted with DMEM basal medium, 150 ⁇ g/mL (DAR : 7.12) or 262.5 ⁇ g/mL (DAR: 3.79) starting, 4-fold dilution, 11 concentration points, add to the corresponding wells, 100 ⁇ L per well, the final serum concentration is 5%; 37°C, 5% CO 2 incubator Incubate in medium for 48 hours; add CCK8 (Rhinogen), 20 ⁇ l/well, 37°C, 5% CO 2 incubator for 0.5-2.5 hours, read with a microplate reader (MD) 450nm every half
  • the experimental results are shown in Figure 10A, Figure 10B and Figure 10C.
  • the 2C6.9-TL001 molecule can effectively kill HEK293T-Claudin18.2 cells.
  • DAR value is 7.12
  • its EC 50 value is 473ng/mL
  • DAR value is 7.12
  • its EC 50 value was 794.1ng/mL.
  • the EC50 value of 2C6.9-TL001 (DAR: 7.12) molecule against HEK293T-Claudin 18.1 was 3900 ng/mL
  • the 2C6.9-TL001 (DAR: 7.12) molecule against Claudin 18.2 cells was significantly higher than Claudin 18.1. Cells (about an 8-fold difference), indicating that this killing effect is specific to Claudin 18.2.
  • Both 2C6.9-TL002 and 2C6.9-TL003 can effectively kill HEK293T-Claudin 18.2 cells, and their EC 50 values are 628.9ng/mL and 540.2ng/mL respectively; 2C6 The EC50 values of 9-TL002 and 2C6.9-TL003 on HEK293T-Claudin18.1 killing activity were 30590ng/mL and 8258ng/mL, respectively. The killing activity of the two on HEK293T-Claudin 18.2 cells was significantly higher than that of Claudin 18.1 cells, indicating that the killing effect of the two is Claudin 18.2 specific.
  • the present invention selects gastric cancer cell line NUGC-4 to detect the killing activity of 2C6.9-TL001 on the endogenously expressing Claudin 18.2 cells.
  • the specific experimental procedures are as follows: the day before the experiment, the cells were diluted with RPMI 1640+10% FBS, 100 ⁇ L/well, and 1*10 ⁇ 4 cells per well were plated overnight; the next day, the 2C6.9-TL001 molecules were gradually diluted with RPMI 1640 medium, Start at 1000 ⁇ g/mL (DAR 7.12) or 1750 ⁇ g/mL (DAR: 3.79), 3 times dilution, 11 concentration points, add to the corresponding wells, 100 ⁇ L per well, the final serum concentration is 5%; 37°C, 5% Incubate in a CO 2 incubator for 72 hours; add CCK8 (Rhinogen), 20 ⁇ l/well, 37°C, 5% CO 2 incubator for 0.5-2.5 hours, read on a microplate reader (MD) at 450nm every half hour and import
  • the killing activity of 2C6.9-TL002 and 2C6.9-TL003 on NUGC-4 cells was detected by the similar experimental method described above.
  • the initial ADC concentration was 500 ⁇ g/mL, diluted 4 times, and 11 concentration points.
  • the experimental results are shown in Figure 11C. Both 2C6.9-TL002 and 2C6.9-TL003 can effectively kill NUGC-4 cells, and their EC 50 values are 54.92 ⁇ g/mL and 123.94 ⁇ g/mL, respectively.
  • the present invention selects NUGC-4 cells to detect the internalization activity of the 2C6.9 antibody.
  • the specific experimental steps are as follows: take NUGC-4 cells, trypsinize and count, resuspend the cells in PBS (containing 1% BSA), adjust the cell density to 3 ⁇ 10 6 /mL; take 100 ⁇ L of the resuspended cells and add the final concentration to 100 ⁇ g/mL 2C6.9-hz21 antibody, with human IgG of the same type as a negative control, incubate on ice for 1 hour; after incubation, wash with pre-cooled PBS 3 times and use NUGC-4 cell culture medium (1640+10% FBS) Resuspend the cells and divide the cells into two parts.
  • endocytosis group [1-(MFI 37°C antibody group -MFI 37°C control group )/(MFI antibody group on ice- MFI ice control group)] ⁇ 100% Internalization rate.
  • the present invention uses Cancer cell line-derived xenograft (CDX) model and patient-derived xenograft (PDX) model to evaluate the anti-tumor effect of ADC molecules.
  • CDX Cancer cell line-derived xenograft
  • PDX patient-derived xenograft
  • NCI-N87-Claudin18.2+Balb/c Nude mouse CDX model Use RPMI1640 medium containing 10% fetal bovine serum (FBS) to culture NCI-N87-Claudin18 under the conditions of 37°C and 5% CO 2. 2 cells. Cells in exponential growth phase were collected, PBS resuspended cells according to the amount of 5 ⁇ 10 6 / is only (suspended in 0.1ml PBS), were inoculated subcutaneously in female Balb / c Nude mice (Beijing Vital River Laboratory Animal Technology Co., Ltd.) Establish a subcutaneous transplanted tumor model, and when the average tumor volume reaches 70-100mm 3 , randomly group according to the tumor volume, 7 in each group.
  • FBS fetal bovine serum
  • the day of grouping is marked as day 0 (Day 0), and the groups are Human IgG1 isotype control antibody (negative control) group (abbreviated as IgG1), 2C6.9-TL001 (DAR: 7.12) 1mg/kg group and 3mg/kg group, 2C6.9-TL002 (DAR: 6.95) 1mg/kg group and 3mg/kg group. All samples were injected via tail vein, twice a week, for a total of 6 administrations.
  • TGI tumor growth inhibition rate
  • TGI(%) [1-(V T end- V T beginning )/(V C end- V C beginning )]*100%
  • V T end mean tumor volume at the end of the experiment in the treatment group
  • V T start mean tumor volume at the beginning of the treatment group
  • V C end the mean tumor volume at the end of the experiment in the negative control group
  • V C start mean tumor volume at the start of administration of the negative control group
  • T/C(%)(tumor volume) (T t /T 0 )/(C t /C 0 ) ⁇ 100%
  • T 0 the average tumor volume of the treatment group at the initial (ie P0)
  • T t The average tumor volume of the treatment group at each measurement
  • C t The average tumor volume of the negative control group at each measurement.
  • 2C6.9-TL001 (DAR: 7.12) has a significant inhibitory effect on the tumor growth of the NCI-N87-Claudin 18.2 gastric cancer xenograft model, and is dose-dependent.
  • TGI tumor inhibition rate
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • P value is compared with IgG1 group; N/A: not applicable; ns: P>0.05, no statistical difference.
  • the NCI-N87-Claudin18.2 subcutaneous transplanted tumor model was established and grouped according to the method in experimental example 12.1.
  • the day of grouping is marked as Day 0, and the groups are Human IgG1 isotype control antibody (negative control) group (IgG1 for short), paclitaxel group (albumin-binding type), 2C6.9 monoclonal antibody and paclitaxel combined group and 2C6.9-TL001 (DAR: 7.12) group. All samples were injected through the tail vein twice a week for 3 weeks. The dosages are shown in Table 9.
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • P value is compared with the IgG1 group; N/A: not applicable; ns: P>0.05, no statistical difference.
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • NUGC-4 cells were cultured with RPMI1640 medium containing 10% fetal bovine serum (FBS) at 37°C and 5% CO 2. Cells in exponential growth phase were collected, PBS resuspended cells according to the amount of 5 ⁇ 10 6 / is only (suspended in 0.1ml PBS), were inoculated subcutaneously in female Balb / c Nude mice (Beijing Vital River Laboratory Animal Technology Co., Ltd.) Establish a subcutaneous transplanted tumor model, and when the average tumor volume reaches about 70-100 mm 3 , randomly group them according to the tumor volume, with 7 in each group.
  • FBS fetal bovine serum
  • the day of grouping is marked as day 0 (Day 0), and the group is Human IgG1 isotype control antibody (negative control) group (abbreviated as IgG1), 2C6.9-TL001 (DAR: 3.79) 5.25 mg/kg group, 2C6.9- TL001 (DAR: 3.79) 17.5 mg/kg group, 2C6.9-TL001 (DAR: 7.12) 3 mg/kg group, 2C6.9-TL001 (DAR: 7.12) 10 mg/kg group (ADC drugs with different DAR values follow the same toxin Carrying out the designed dose for the load). All samples were injected through the tail vein, twice a week, for a total of 3 weeks. The dosages are shown in Table 11.
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • P value is compared with IgG1 group
  • N/A Not applicable.
  • mice There are 3 groups: Human IgG1 isotype control antibody (negative control) group (IgG1 10mg/kg), 2C6.9-TL001-DAR7.12 3mg/kg group and 10mg/kg group. All samples were injected via tail vein, twice a week, for a total of 5 administrations. After the administration, observe and regularly measure the tumor volume and body weight of the mice. The measurement method is as described in Experimental Example 12.1.
  • 2C6.9-TL001-DAR7.12 has a significant inhibitory effect on the tumor growth of the GA0006 gastric cancer PDX model, and is dose-dependent.
  • the tumor inhibition rate (TGI) of the 3 mg/kg group was as high as 94.72%, and 4 of them were partially resolved; the TGI of the 10 mg/kg group reached 124.49%, All 7 tumors regressed, indicating that 2C6.9-TL001 can effectively inhibit tumor growth. All treatment groups had no significant weight loss during the observation period, and the animals were well tolerated.
  • Table 12 Gastric cancer GA0006+Balb/c Nude mouse PDX model
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • the experimental results are shown in Table 13 and Figures 12I and 12J.
  • 2C6.9-TL001-DAR7.12 has a significant inhibitory effect on the tumor growth of the GA0006 gastric cancer PDX model, and is dose-dependent.
  • the tumor inhibition rate (TGI) of the 3 mg/kg group was as high as 103.76%, and 6 tumors were partially resolved; the 10 mg/kg group TGI reached 113.70%, and all 7 tumors resolved, indicating 2C6.9- TL001 can effectively inhibit tumor growth. All treatment groups had no significant weight loss during the observation period, and the animals were well tolerated.
  • Table 13 Gastric cancer GA0006+Balb/c Nude mouse PDX model
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • the NCI-N87-Claudin18.2 subcutaneous transplanted tumor model was established according to the method in Experimental Example 12.1.
  • the day of grouping is marked as Day 0, and the group is Human IgG1 isotype control antibody (negative control) group (IgG1 for short), 2C6.9-TL001 (DAR: 7.40) 0.3 mg/kg group, 1 mg/kg group And 3mg/kg group. All samples were injected via tail vein, twice a week, for a total of 6 administrations. The dosages are shown in Table 14.
  • the experimental results are shown in Table 14 and Figures 12K and 12L. Stopping the drug after 6 doses extends the observation to the 31st day (31st day after the first dose). Compared with the negative control group, 2C6.9-TL001 0.3 mg
  • the tumor inhibition rate (TGI) in the 1 mg/kg group was 34.04%, while the TGI in the 1 mg/kg group and 3 mg/kg group were as high as 122.57% (partial regression of tumors in all mice) and 184.22% (all tumors in 4 mice subsided, 4 hours). The mouse tumor partially subsided).
  • the mice in all treatment groups had no significant weight loss during the observation period, and the animals had good tolerance.
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • HEK293T-Claudin 18.2 cells (human embryonic kidney cells) were cultured in DMEM medium containing 3 ⁇ g/mL puromycin and 10% fetal bovine serum (FBS) at 37° C. and 5% CO 2. Collect exponential growth phase cells, resuspend in PBS, and inoculate subcutaneously in female Balb/c Nude mice (Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd.) according to the amount of 1 ⁇ 10 7 cells per mouse (suspended in 0.1ml PBS) Establish a subcutaneous transplanted tumor model. When the average tumor volume reaches about 120-140mm 3 , randomly group them according to the tumor volume, with 8 in each group.
  • FBS fetal bovine serum
  • the day of grouping is marked as Day 0, and the group is Human IgG1 isotype control antibody (negative control) group (IgG1 for short), 2C6.9-TL001 (DAR: 7.40) 0.3 mg/kg group, 1 mg/kg group And 3mg/kg group. All samples were injected through the tail vein, twice a week, for a total of 6 administrations. The dosages are shown in Table 15.
  • the experimental results are shown in Table 15 and Figures 12M and 12N.
  • 2C6.9-TL001 DAR: 7.40
  • HEK293T-Claudin18 The tumor growth of human embryonic kidney cell transplantation tumor model has a significant inhibitory effect, and it is dose-dependent.
  • 2C6.9-TL001 The tumor inhibition rate (TGI) of the 0.3 mg/kg group was 70.99% (all tumors in 1 mouse disappeared); while the TGI of the 1 mg/kg group and the 3 mg/kg group were 94.98% (2 mice Partial tumor regression) and 182.81% (2 mice with partial tumor regression, 6 mice with all tumor regression).
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • NUGC-4 cells were cultured with RPMI1640 medium containing 10% fetal bovine serum (FBS) at 37°C and 5% CO 2. Collect exponential growth phase cells, resuspend in PBS, and inoculate subcutaneously in female Balb/c Nude mice (Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd.) according to the cell volume of 5 ⁇ 10 6 per mouse (suspended in 0.1ml PBS) , Establish a subcutaneous transplanted tumor model. When the average tumor volume reaches about 80mm 3 , randomly group them according to the tumor volume, with 8 in each group.
  • FBS fetal bovine serum
  • the day of grouping was recorded as Day 0, and the groups were Human IgG1 isotype control antibody (negative control) group (abbreviated as IgG1), 2C6.9-TL001 (DAR: 7.40) 3 mg/kg group and 10 mg/kg group. All samples were injected through the tail vein, twice a week, for a total of 6 administrations. The dosages are shown in Table 16.
  • 2C6.9-TL001 (DAR: 7.40) is effective against NUGC-4 gastric cancer.
  • the tumor growth of the transplanted tumor model has a significant inhibitory effect, and it is dose-dependent.
  • 2C6.9-TL001 The tumor inhibition rate (TGI) of the 3mg/kg group was 56.62%; while the TGI of the 10mg/kg group was 90.28% (2 mice with partial tumor regression).
  • TGI tumor growth inhibition rate
  • T/C relative tumor proliferation rate
  • PR partial tumor regression
  • CR full tumor regression.
  • the P value is compared with the IgG1 group
  • N/A Not applicable.
  • 2C6.9-TL001 in the present invention can effectively inhibit the growth of Claudin 18.2 positive expression tumors in a dose-dependent manner, and has good safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2021/093348 2020-05-15 2021-05-12 抗体药物缀合物及其制备方法和用途 Ceased WO2021228141A1 (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PE2022002658A PE20230373A1 (es) 2020-05-15 2021-05-12 Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo
JP2022568760A JP7407973B2 (ja) 2020-05-15 2021-05-12 抗体薬物複合体、その調製方法、およびその使用
EP21804105.1A EP4151235A4 (en) 2020-05-15 2021-05-12 ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS USE
KR1020227043736A KR20230012000A (ko) 2020-05-15 2021-05-12 항체 약물 컨쥬게이트, 이의 제조 방법 및 이의 용도
IL298184A IL298184A (en) 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof
MX2022014332A MX2022014332A (es) 2020-05-15 2021-05-12 Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo.
AU2021270940A AU2021270940A1 (en) 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof
US17/998,772 US20230338565A1 (en) 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof
CR20220580A CR20220580A (es) 2020-05-15 2021-05-12 Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CA3178406A CA3178406A1 (en) 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof
CN202180032620.1A CN115715202B (zh) 2020-05-15 2021-05-12 抗体药物缀合物及其制备方法和用途
JOJO/P/2022/0306A JOP20220306A1 (ar) 2020-05-15 2022-11-10 مترافق جسم مضاد-عقار، طريقة تحضيره واستخدامه
CONC2022/0016208A CO2022016208A2 (es) 2020-05-15 2022-11-11 Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
DO2022000251A DOP2022000251A (es) 2020-05-15 2022-11-14 Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
JP2023213677A JP7734178B2 (ja) 2020-05-15 2023-12-19 抗体薬物複合体、その調製方法、およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010410633.5 2020-05-15
CN202010410633 2020-05-15

Publications (1)

Publication Number Publication Date
WO2021228141A1 true WO2021228141A1 (zh) 2021-11-18

Family

ID=78525267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/093348 Ceased WO2021228141A1 (zh) 2020-05-15 2021-05-12 抗体药物缀合物及其制备方法和用途

Country Status (18)

Country Link
US (1) US20230338565A1 (https=)
EP (1) EP4151235A4 (https=)
JP (2) JP7407973B2 (https=)
KR (1) KR20230012000A (https=)
CN (1) CN115715202B (https=)
AU (1) AU2021270940A1 (https=)
CA (1) CA3178406A1 (https=)
CL (2) CL2022003170A1 (https=)
CO (1) CO2022016208A2 (https=)
CR (1) CR20220580A (https=)
DO (1) DOP2022000251A (https=)
EC (1) ECSP22089507A (https=)
GE (2) GEP20257719B (https=)
IL (1) IL298184A (https=)
JO (1) JOP20220306A1 (https=)
MX (1) MX2022014332A (https=)
PE (1) PE20230373A1 (https=)
WO (1) WO2021228141A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098515A1 (zh) * 2021-12-02 2023-06-08 四川科伦博泰生物医药股份有限公司 一种药物-接头偶联物的制备方法
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
WO2024012523A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2024109840A1 (zh) 2022-11-22 2024-05-30 康诺亚生物医药科技（成都）有限公司 稠环类化合物及其偶联物和用途
WO2024175042A1 (zh) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 药物偶联物治疗肿瘤疾病的用途及方法
WO2024179561A1 (en) * 2023-03-02 2024-09-06 Multitude Therapeutics Inc. Antibody-drug conjugates, pharmaceutical compositions and uses thereof
WO2024222870A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024255880A1 (en) * 2023-06-16 2024-12-19 Fortvita Biologics (Singapore) Pte. Ltd. A method for treatment of solid tumors with an antibody-drug conjugate targeting claudin 18.2
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CN101312989A (zh) 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
WO2019149116A1 (zh) * 2018-01-30 2019-08-08 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
WO2019154120A1 (zh) * 2018-02-11 2019-08-15 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18．2抗体的药物偶联体及其制备方法和用途
WO2020135201A1 (zh) * 2018-12-28 2020-07-02 四川科伦博泰生物医药股份有限公司 一种抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US9056092B2 (en) * 2011-12-02 2015-06-16 Ethicon, Inc. Hemostatic bioabsorbable device with polyethylene glycol binder
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3725798B1 (en) * 2017-12-15 2026-03-04 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Bioactive conjugate, preparation method therefor and use thereof
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
US20230192903A1 (en) * 2020-05-29 2023-06-22 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody against cldn18.2 and cd3

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (https=) 1980-08-07 1988-10-18
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CN101312989A (zh) 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
WO2019149116A1 (zh) * 2018-01-30 2019-08-08 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
WO2019154120A1 (zh) * 2018-02-11 2019-08-15 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18．2抗体的药物偶联体及其制备方法和用途
WO2020135201A1 (zh) * 2018-12-28 2020-07-02 四川科伦博泰生物医药股份有限公司 一种抗体及其用途

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"Gene", Database accession no. NM 001002026.2
"Remington's Pharmaceutical Sciences", 1995, PENNSYLVANIA: MACK PUBLISHING
ALFTHAN ET AL., PROTEIN ENG., vol. 8, 1995, pages 725 - 731
ALTSCHUL SF ET AL., NATURE GENET., vol. 6, 1994, pages 119
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, NATIONAL INSTITUTES OF HEALTH, pages: 51 - 63
BRUGGERMANN ET AL., YEAR IN IMMUNOLOGY, vol. 7, 1993, pages 33
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
CHOTHIA & LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 546 - 883
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 402
D. WILKINSON: "The Scientist", vol. 14, 17 April 2000, THE SCIENTIST, INC., pages: 25 - 28
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17
HIGGINS DGSHARP PM, CABIOS, vol. 5, 1989, pages 151
HOLLIGER ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 1126 - 1136
HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 6448
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 - 597
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
JAKOBOVITS ET AL., NATURE, vol. 361, 1993, pages 186 - 187
JONES ET AL., NATURE, vol. 321, 1986, pages 522 525
KABAT, EA ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LEFRANC ET AL., DEV. COMPARAT. IMMUNOL., vol. 27, 2003, pages 55 - 77
LO, BENNY, KC: "Antibody Engineering: Methods and Protocols", vol. 248, 2004, HUMANA PRESS
LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859
MARTIN AC R: "Protein sequence and structure analysis of antibody variable domains[M] //Antibody engineering", 2010, SPRINGER, pages: 33 - 51
MARTIN ACRCHEETHAM JCREES AR: "Modelling antibody hypervariable loops: A combined algorithm", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 9268 - 9272, XP000165667, DOI: 10.1073/pnas.86.23.9268
MOHAMMADI Z, MOL BIOTECHNOL., vol. 57, no. 9, September 2015 (2015-09-01), pages 793 - 800
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 6855
MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages 220
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
POLJAK RJ ET AL., STRUCTURE, vol. 113, 1994, pages 1121 - 1123
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 596
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 329
ROOVERS ET AL., CANCER IMMUNOL, 2001
See also references of EP4151235A4
SMITH TFWATERMAN MS, ADV.APPL.MATH., vol. 2, 1981, pages 482
VAUGHAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309 - 103

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098515A1 (zh) * 2021-12-02 2023-06-08 四川科伦博泰生物医药股份有限公司 一种药物-接头偶联物的制备方法
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
WO2024012523A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2024109840A1 (zh) 2022-11-22 2024-05-30 康诺亚生物医药科技（成都）有限公司 稠环类化合物及其偶联物和用途
EP4623936A1 (en) 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024175042A1 (zh) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 药物偶联物治疗肿瘤疾病的用途及方法
WO2024179561A1 (en) * 2023-03-02 2024-09-06 Multitude Therapeutics Inc. Antibody-drug conjugates, pharmaceutical compositions and uses thereof
WO2024222870A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
WO2024255880A1 (en) * 2023-06-16 2024-12-19 Fortvita Biologics (Singapore) Pte. Ltd. A method for treatment of solid tumors with an antibody-drug conjugate targeting claudin 18.2
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Also Published As

Publication number Publication date
ECSP22089507A (es) 2023-02-28
EP4151235A1 (en) 2023-03-22
CN115715202B (zh) 2025-11-04
JP7734178B2 (ja) 2025-09-04
JP2024037960A (ja) 2024-03-19
PE20230373A1 (es) 2023-03-06
MX2022014332A (es) 2022-12-13
GEAP202416114A (en) 2024-08-26
GEP20257719B (en) 2025-01-27
CL2022003170A1 (es) 2023-05-19
CN115715202A (zh) 2023-02-24
JP2023525120A (ja) 2023-06-14
IL298184A (en) 2023-01-01
CO2022016208A2 (es) 2023-02-27
CA3178406A1 (en) 2021-11-18
JP7407973B2 (ja) 2024-01-04
CL2024002956A1 (es) 2025-01-24
KR20230012000A (ko) 2023-01-25
DOP2022000251A (es) 2023-04-16
US20230338565A1 (en) 2023-10-26
AU2021270940A1 (en) 2022-12-15
CR20220580A (es) 2023-04-11
JOP20220306A1 (ar) 2022-11-10
EP4151235A4 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
CN115715202B (zh) 抗体药物缀合物及其制备方法和用途
CN113166246B (zh) 一种抗体及其用途
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
EP2552966B1 (en) Antibodies against csf-1r
WO2023143263A1 (zh) 一种针对Her3的抗体，偶联物及其用途
EP4292611A1 (en) Anti-cd112r antibody and use thereof
WO2021063201A1 (zh) 抗pd-1抗体及其用途
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
CN113227142A (zh) 抗pd-1抗体及其用途
JP2021516537A (ja) Ｃ−ｍｅｔ結合剤
WO2024222384A1 (zh) 抗ptk7抗体及其用途
CN111818972A (zh) 去免疫的抗erbb3抗体
TW202430557A (zh) Ａｎｔｉ－Ｍｅｔ抗體、抗體藥物偶聯物及其製備方法和用途
WO2023246701A1 (zh) 一种抗体及其用途
KR20250034296A (ko) Cd117을 표적화하는 항체
WO2023078386A1 (zh) 抗cldn18.2抗体及其用途
HK40090265A (en) Antibody drug conjugate, preparation method therefor and use thereof
EA050737B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и его применение
HK40048164B (zh) 一种抗体及其用途
WO2025124443A1 (zh) Adam9结合蛋白及其用途
CN121949552A (zh) Anti-cMet抗体、抗体药物偶联物及其制备方法和用途
KR20250111754A (ko) 항-ccr8 모노클로날 항체 및 이의 치료적 용도
CN116848144A (zh) 抗pd-l1抗体及其用途
HK40048164A (en) Antibody and use thereof
HK40050386B (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21804105

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3178406

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022568760

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2022/0016208

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 140150140003005951

Country of ref document: IR

WWE Wipo information: entry into national phase

Ref document number: 202217065484

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022023095

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227043736

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 16114

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2021270940

Country of ref document: AU

Date of ref document: 20210512

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021804105

Country of ref document: EP

Ref document number: DZP2022001026

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2021804105

Country of ref document: EP

Effective date: 20221215

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: NC2022/0016208

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112022023095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221111

WWE Wipo information: entry into national phase

Ref document number: 522441319

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 140150140003005951

Country of ref document: IR

WWP Wipo information: published in national office

Ref document number: 140150140003005951

Country of ref document: IR

WWR Wipo information: refused in national office

Ref document number: 522441319

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 202180032620.1

Country of ref document: CN

WWW Wipo information: withdrawn in national office

Ref document number: 794486

Country of ref document: NZ